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ABSTRACT
Drug metabolism is an important area of pharmaceutical research as it has 
significant effects on safety and efficacy of the therapy. Cytochrome P450 
(CYP) enzymes metabolize the majority of clinically used drugs and have thus 
a critical role in their elimination process. Alterations in CYP activities can lead 
to unexpected adverse effects and toxicity (low activity), or on the other hand 
to complete lack of efficacy (high activity). Wide inter-individual variation in 
CYP activities is observed due to polymorphism as well as other individual and 
external factors. The emerging approach, called precision medicine, aims to 
increase the efficacy and safety of the treatment by considering the individual 
characteristic of the patient. The medication is then prescribed based on this 
information together with the diagnosis. Individual variation in CYP activities 
is one of the factors that should be considered when designing the treatment. 
Another aspect of precision medicine is targeted drug delivery with help of 
nanocarriers, which enables controlled release and accumulation of the drug 
at the targeted site. This approach improves the bioavailability of the drug and 
thus also the efficacy of the treatment, whereas side effects and toxicity can be 
decreased. 
Chemical analysis of a variety of different samples is involved in all areas 
of pharmaceutical research. Miniaturization of the analytical techniques 
results in fast and simple analysis of small sample volumes with reduced costs. 
Simple and portable miniaturized analytical devices have also enabled point-
of-care analysis in e.g., doctor’s office. These techniques could provide 
valuable tools also for precision medicine and screening of the individual 
characteristics. However, the robustness, precision, and sensitivity of the 
microfluidic analytical devices should be further addressed before these 
techniques can compete with conventional methods in pharmaceutical 
research. The aim of this thesis was to evaluate the feasibility of microfluidic 
analytical techniques for pharmaceutical research. A particular emphasis was 
put on drug metabolism and its impacts on precision medicine. 
In the first subproject of this thesis, the effect of nanoformulations on CYP 
metabolism were determined in vitro. Three types of porous silicon (PSi) 
nanoparticles and three polymers commonly used in the same 
nanoformulations were investigated. Statistically significant alterations were 
observed in activities of the studied isoenzymes in the presence of the PSi 
nanoparticles, whereas polymers had less effect on the enzyme kinetic 
parameters. The highly polymorphic CYP2D6 was found to be most prone to 
inhibition by both the nanoparticles and the polymers. The results 
demonstrate the risk of interactions caused by other components of the 
(nano)formulations than the active ingredients. The effects of nanocarriers on 
CYP metabolism should be further investigated both in vitro and in vivo, to be 
able to evaluate the overall effects on CYP metabolism. 
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In the second subproject, a paper microfluidic assay was developed for 
rapid screening of the inter-individual differences in CYP enzyme activities. 
The multiplexed microfluidic lateral flow assay was based on a paper-like 
functionalized calcium carbonate coating and inkjet printed hydrophobic fluid 
barriers. The assay was applied to study of individual differences in CYP2A6 
and CYP1A2 activities in (human) liver microsomes (HLM) of individual 
donors. The determined CYP activities were compared to average activities in 
a 20-donor subpopulation. The results showed both increased and decreased 
enzyme activities in the HLM of individual donors compared to the pooled 
HLM. However, based on the comparison to in-solution assays, further 
validation of the microfluidic lateral flow assay is needed to reach the 
robustness and sensitivity required for routine use. 
In the third subproject, a commercial microchip electrophoresis (MCE) 
device with integrated electrochemical (EC) detection was applied to CYP 
metabolism studies and to analysis of morphine in mouse plasma and brain 
samples. The method developed for analysis of CYP metabolites showed good 
selectivity and precision. However, the sensitivity of the MCE-EC method was 
found insufficient for CYP metabolism studies. Instead, MCE-EC was shown 
to be feasible for quantitation of intraperitoneally administered morphine in 
mouse plasma and brain. Quantitation of morphine from biological samples 
was achieved with good precision and accuracy after off-chip liquid-liquid 
extraction (LLE) and on-chip electrokinetic stacking demonstrating the 
capability of MCE in targeted quantitative analysis. 
In the fourth subproject, MCE was combined with electrospray ionization-
mass spectrometry (ESI-MS). The method was applied to separation of 
phosphorylated peptides, particularly the positional phosphorylation isomers, 
which is a challenging task for conventional analytical techniques. The 
feasibility of the method was demonstrated with the help of 
monophosphorylated and triply phosphorylated insulin receptor peptides, 
which could be separated from the nonphosphorylated peptide in less than 
40 s. The separation of the monophosphorylated peptide isomers from each 
other was achieved after derivatization. 
In conclusion, with help of selected applications, this thesis demonstrates 
the advances that microfluidics could provide for conventional pharmaceutical 
analysis and drug metabolism studies. MCE was shown to be suitable for 
quantitative analysis with good precision and selectivity. Sensitivity is a 
common challenge in the field of microfluidics, but with carefully selected 
method for each application, these techniques can reach the benefits of 
miniaturized analytical devices. Further improvements in integration of the 
sample pretreatment and enrichment on the same microchip would also 
enhance the sensitivity as well as decrease the variation associated with 
manual sample handling.  
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4-methylcoumarin 
APTES-TCPSi aminopropylsilane-modified thermally carbonized porous 
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CEC 3-cyano-7-ethoxycoumarin 
CHC 3-cyanoumbelliferone (3-cyano-7-hydroxycoumarin) 
chipLC microchip liquid chromatography 
CLint intrinsic clearance 
CV coefficient of variation 
CYP cytochrome P450 (enzyme) 
EC electrochemical detection 
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ePAD electrochemical paper-based analytical device 
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ex/em excitation/emission (wavelengths) 
FCC functionalized calcium carbonate 
FDA the United States (U.S.) Food and Drug Administration 
Fmoc-Cl 9-fluorenylmethyl chloroformate 
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IR1A/B  monophosphorylated insulin receptor peptide 
 (isomers A and B) 
IR3 triply phosphorylated insulin receptor peptide 
Km Michaelis constant 
LC liquid chromatography 
Leff effective separation length 
LIF laser-induced fluorescence 
LLE liquid-liquid extraction 
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LOD limit of detection 
(L)LOQ (lower) limit of quantitation 
MCE microchip capillary electrophoresis 
ME methyl ether 
MES 2-(N-morpholino)-ethanesulfonic acid 
MS mass spectrometry 
MS/MS tandem mass spectrometry 
μPAD microfluidic paper-based analytical device 
μTAS miniaturized total (chemical) analysis system 
NADPH β-nicotinamide adenine dinucleotide 2’-phosphate 
PDMS polydimethyl siloxane 
PSi porous silicon 
PVA polyvinyl alcohol 
Q-TOF quadrupole-time of flight (mass spectrometer) 
RE reference electrode 
Rf retention factor 
TCPSi thermally carbonized porous silicon 
UPLC ultrahigh pressure liquid chromatography 
UV ultraviolet 
Vmax maximal enzyme activity 
WE working electrode 
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1 INTRODUCTION
Chemical analysis of a sample consists of multiple steps including sample 
pretreatment, injection/introduction of the sample to the analytical system, 
separation, and detection of the analytes. The concept of a miniaturized total 
(chemical) analysis system (μTAS), combining all these steps on a single 
device, was first introduced almost 30 years ago.[1] By reducing the size of the 
analytical system, the sample and solvent consumption is decreased and the 
analysis times are shorter compared to conventional analytical systems, which 
commonly results also in reduced costs. Small size combined with integration 
of all analytical steps open up possibilities for portable devices and 
parallelization. 
In drug discovery and development, the possibility for fast screening of e.g., 
metabolic properties could enhance the process and decrease the costs 
significantly. The conventional analytical systems are often too slow for 
screening of large amount of new drug candidates in the early phases of the 
development process. However, early identification of properties not 
preferable for a drug compound and termination of the development process 
will decrease the time and money spent in the later, more expensive 
development phases. Metabolic profile of the new drug candidate, including 
also the inhibitory and inductive effects, is one of these important properties 
that should be investigated in early phase of the development. 
Drug metabolism refers to the enzymatic reactions taking place in the 
human body after administration of the drug. These reactions modify the drug 
so that it is more easily excreted. Metabolism can be divided in to two phases 
based on the reaction types: phase I reactions are mainly oxidation and 
reduction reactions that result in new functional groups that can then be 
conjugated in phase II reactions. The phase I reactions are catalyzed mainly 
by cytochrome P450 (CYP) enzymes, and a majority (70–80%) of drugs in 
clinical use as well as many other xenobiotics are metabolized by these 
enzymes.[2,3] Miniaturized analytical systems could provide simple and fast 
methods for screening of the metabolic properties of new drug candidates in 
reasonable time. 
Miniaturized analytical devices are also commonly applied to point-of-care 
diagnostic systems.[4] These systems are ideally simple, fast, and low-cost 
devices that enable immediate result without additional laboratory equipment 
or trained personnel, e.g. in the doctor’s office. Traditionally, the doctor 
prescribes a medication for a patient based on the diagnose. Current research 
has, however, been directed more towards tailoring of the treatment based on 
individual characteristics (including metabolic activity) instead of "one-size-
fits-all" type of medication. The idea of this emerging approach called 
precision medicine, is to recognize the individual characteristics affecting to 
the treatment, and to select the most effective and safe medication for each 
Introduction 
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patient. The U.S. National Research Council recommends the term precision 
medicine to be used instead of the term personalized medicine, as the latter 
can be misinterpreted to refer to development of unique medications.[5] The 
adoption of precision medicine principles for widespread use requires fast and 
simple techniques for screening of the individual characteristics e.g., by 
miniaturized analytical techniques. Targeted drug delivery, with the help of 
nanocarriers, is another precision medicine approach.[6] The controlled 
release of the drug from the nanoformulation at the targeted site increases the 
bioavailability and efficacy, but also decreases the adverse effects and toxicity. 
In this thesis, different miniaturized analytical systems were evaluated 
targeting selected analytical challenges in pharmaceutical research, drug 
metabolism, and the individual differences in CYP enzyme activities. 
Pharmaceutical nanoformulations, based on porous silicon (PSi) 
nanoparticles, were examined in terms of their effects on drug metabolism (I). 
In publication II, a simple microfluidic paper-based platform was developed 
and characterized for screening of individual differences in CYP enzyme 
activities. The feasibility of microchip electrophoresis (MCE) was investigated 
in three different applications. A simple, commercial device with integrated 
amperometric detection was used for CYP metabolism studies and for 
quantitative analysis of a targeted analyte in biological samples (III). A 
customized MCE system combined to mass spectrometry was applied for 
separation of phosphopeptides, including phosphorylation isomers (IV). 
1.1 ROLE OF DRUG METABOLISM IN EFFICACY AND 
SAFETY OF THE TREATMENT
Identification of the efficacy and safety of a new drug candidate is a key point 
in drug discovery and development. Appropriate balance of safety and efficacy 
depends on the indication (severity of the condition, other available 
medications) and it can be evaluated by calculating the therapeutic index.[7] 
Traditionally therapeutic index is calculated as the ratio of the highest dose 
without toxic effects to the dose with the desired effect. Also exposure to the 
drug can be used instead of the actual dose as it considers also the variation 
between individuals, whereas same dose can result in different exposure 
levels. There is no universal limit of acceptable therapeutic index, but generally 
higher value describes more preferable safety profile. Instead, low therapeutic 
index may be acceptable for treatment of life-threatening diseases, especially 
if other options for treatment do not exist. 
Drug metabolism has a major role in the efficacy and safety of the 
medication through the pharmacokinetic properties. Thus, drug metabolism 
research is one of the key points in drug discovery and development.[8] Fast 
metabolism, especially before the drug even reaches systemic blood circulation 
(first-pass metabolism), leads to low bioavailability for orally administered 
drugs. The metabolism of a new drug candidate should be well characterized 
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also to identify the functional groups most prone to metabolism (soft spots). 
The properties of the compound can then be further modified by blocking 
these soft spots. An ideal drug compound, from metabolism perspective, 
would not affect the activity of drug-metabolizing enzymes, and it would be 
metabolized by multiple enzymes, instead of only one.[8] These issues are 
further discussed in the following chapters. If reactive metabolites are formed, 
they may in turn react rapidly with e.g., cellular proteins or DNA, resulting in 
toxic effects [8,9] and thus, these are usually avoided. 
CYP enzymes are the main drug metabolizing enzymes and they exist in all 
tissues, while they are most abundant in liver and small intestine.[10] These 
membrane-bound hemoproteins are mainly located in the endoplasmic 
reticulum of the cells.[11] Currently 18 families and 44 subfamilies of CYPs are 
known, but the enzymes metabolizing xenobiotics (including drugs) belong to 
families 1–3.[10] The other CYP enzymes participate in endogenous functions 
like biosynthesis of steroids and cholesterol, vitamin metabolism, and 
oxidation of unsaturated fatty acids. The CYP isoforms participating in drug 
metabolism and the fraction of drug compounds metabolized by each of them 
are presented in Figure 1. 
 
Figure 1 Factors affecting the cytochrome P450 activity and the fraction of clinically relevant 
drugs metabolized by the different isoforms (based on analysis of 248 drug 
metabolism pathways). Only the major contributing isoform is included for each 
metabolic pathway. The most important factors affecting enzyme activity are bolded 
and the arrows indicate the direction of the change (↑: increased activity; ↓: decreased 
activity). The effect of factors listed in parenthesis is controversial. Reproduced from 
ref. [3] originally published in Pharmacology and Therapeutics licensed under CC BY-
NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/). 
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1.1.1 INDIVIDUAL CHARACTERISTICS AFFECTING DRUG 
METABOLISM
The activity of the CYP enzymes varies a lot between individuals and can lead 
to unexpected consequences in terms of safety and efficacy, if not carefully 
considered.[3] Generally, decreased enzyme activity results in high and even 
toxic concentration levels, whereas increased activity causes unintentionally 
low concentrations and lack of efficacy. The factors affecting CYP activity 
include genetic differences, other individual factors (age, sex), as well as 
inhibition or induction by drugs or other xenobiotics. The importance of these 
factors differs also between the different isoenzymes: for example, CYP2D6 is 
mainly affected by polymorphism and has been generally considered 
noninducible [3], even though some studies showing possible induction have 
also been published.[12] Instead, CYP3A4 is induced by a wide variety of 
substances and is also strongly affected by sex. The factors affecting enzyme 
activity, with examples of their clinical impact, are discussed in the following 
chapters. 
Genetic polymorphism of cytochrome P450 enzymes
Polymorphism of CYP enzymes causes notable inter-individual and inter-
ethnic differences in enzyme activities and thus alterations in efficacy, safety, 
and adverse effects of drugs. It has been estimated that out of all drug 
therapies, 20–25% result in unexpected outcome due to polymorphism mainly 
related to CYP enzymes.[13,14] To avoid these risks related to polymorphism, 
a new drug candidate should preferably be metabolized by multiple enzymes 
rather than just a single one [8], as mentioned previously. 
The variations in CYP genes include single nucleotide polymorphism 
(substitution, insertion, or deletion of a single nucleotide) and copy number 
variation (gene duplication or deletion).[10,14] The enzymes most affected by 
polymorphism are CYP2D6, CYP2C19, CYP2C9, CYP2B6, CYP3A5, and 
CYP2A6.[3] People can be divided in to ultrarapid metabolizers, extensive 
metabolizers, intermediate metabolizers, and poor metabolizers.[3,10,14] The 
ultrarapid metabolizers have more than two active genes encoding a single 
CYP enzyme and they typically suffer from poor efficacy of drug therapies due 
to rapid elimination of the active drug. Extensive metabolizers are the 
“normal” phenotype with two functional genes, and usually the majority of the 
population belongs to this group. Intermediate metabolizers can have either 
one functional and one defective allele, or two partially defective alleles. Poor 
metabolizers are completely lacking the functional enzyme either due to 
defective gene or due to deletion of the gene, which may expose them to 
adverse effects and toxic doses. 
The different types of metabolizers are not equally localized across the 
world, but significant ethnic differences have been observed.[15] For example, 
increased activity of CYP2D6, due to gene duplication, is most common in 
certain African populations (up to 29%) [15] and it can cause ultrarapid 
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elimination of e.g., tricyclic antidepressants resulting in inefficient 
treatment.[16] The duplication of CYP2D6 gene may also result in e.g., 
ultrarapid metabolism of opioid painkiller tramadol to its active metabolite, 
which can cause respiratory depression if the patient’s renal function is also 
decreased.[17] In turn, polymorphism of CYP2D6 resulting in decreased 
enzyme function is observed with highest frequency in East Asian population 
(70.3%).[15] These poor metabolizers have higher risk for adverse effects of 
e.g., antipsychotic risperidone, which may end up in termination of the 
treatment.[18] Another example is the CYP2C9 deficiency, most commonly 
observed in Europeans, Africans and South Asians, which is at least partly 
involved in the wide inter-individual differences in doses of the anticoagulant 
warfarin, and the difficulty of some patients to reach the narrow therapeutic 
window.[15,19]. The typical initial doses of warfarin may cause high risk of 
bleeding if the patient is poor metabolizer but the dose is not adjusted 
accordingly. CYP2A6 deficiency is in turn most commonly observed in 
Japanese and Korean populations with frequencies of 50.5% and 42.9%, 
respectively, compared to only 9.1% in white populations.[20] This results in 
notable differences e.g., in the rate of nicotine metabolism catalyzed by 
CYP2A6. 
Other individual characteristics affecting cytochrome P450 activity
In addition to polymorphic differences, other individual characteristics, 
including sex, age, and diseases, affect the activity of CYP enzymes 
(Figure 1).[2,3,10] Sex-related differences in CYP activities show higher 
activity of CYP2D6, CYP3A4 and CYP2A6 in females than males, whereas 
CYP1A and CYP2E1 are more active in males.[3,21–23] 
The effect of age is observed as decrease in metabolism capacity during the 
first year of life and in old age.[3] The enzyme system is not fully developed in 
neonates, and instead of the CYP3A4 of adults, the most prominent enzyme of 
the CYP3A subfamily during fetal period is CYP3A7. In elderly people, 
decrease in enzyme activity or expression have not been observed (rather the 
opposite), even though the ability to metabolize drugs is clearly 
decreased.[3,22] This difference might be related to common use of multiple 
medications affecting the enzyme activities, and to decreased blood flow in 
liver. 
CYP activities are also altered in many diseases, but the effects vary 
between the different CYP enzymes from decreased to increased activity.[24–
26] In liver diseases the loss of functional hepatocytes is one of the 
mechanisms causing decreased activities of CYP enzymes, while other factors 
may also exists. CYP1A, CYP2C19, and CYP3A activities are generally most 
decreased [26], but the effects on different CYPs are also dependent on the 
etiology and severity of the liver disease. For example, in nonalcoholic fatty 
liver disease the expression and activity of CYP1A2, CYP2C19, CYP2D6, and 
CYP3A4 are decreased together with progress of the disease, whereas activities 
Introduction 
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of CYP2A6 and CYP2C9 are increased.[25] In addition to liver diseases, also 
infections, inflammations, and cancers typically decrease the expression of 
CYP enzymes.[3,27,28] Also, obesity results generally in decreased CYP 
activity, except CYP2C and CYP2E1 enzymes, that may show even increased 
activities.[29] 
1.1.2 EXTERNAL FACTORS AFFECTING DRUG METABOLISM
Enzyme inhibition and induction by external chemicals also affect drug 
metabolism, occurrence of adverse effects, and efficacy of the medication due 
to decreased or increased enzyme activity. Today, if a new drug candidate is 
found to have a high risk of drug-drug interactions, the development is 
typically terminated.[8] Enzyme induction mechanisms are typically quite 
complex and there is lots of variability between different isoenzymes.[30] 
However, in most cases induction results from increased protein synthesis via 
ligand activation of key receptor transcription factors, e.g., pregnane X 
receptor (PXR), constitutive androstane receptor (CAR), or aryl hydrocarbon 
receptor (AhR). 
Enzyme inhibition
Enzyme inhibitors are classified to irreversible and reversible inhibitors, and 
the latter are subdivided to competitive, noncompetitive, and uncompetitive 
inhibitors (Figure 2).[31] In reversible inhibition, the inhibitor usually binds 
to the enzyme easily, but not permanently. In competitive inhibition, the 
substrate and the inhibitor compete for binding to the same active site of the 
enzyme, whereas in noncompetitive inhibition the inhibitor binds to a 
different site and changes the conformation of the enzyme so that the substrate 
is unable to bind to the active site. Uncompetitive inhibition takes place only 
after formation of enzyme-substrate complex. Mixed-type inhibitors with 
properties of both competitive and noncompetitive inhibitors are also 
commonly observed. Irreversible inhibitor is typically metabolized by the CYP 
enzyme to form a reactive metabolite which binds covalently to the enzyme 
and causes permanent inactivation.[31,32] The activity recovers only after 
synthesis of new enzymes. 
CYP enzymes can be inhibited by drugs, but also by other chemicals, e.g. 
pesticides, or by dietary substances. A well-known and widely investigated 
example of food-drug interaction is the irreversible inhibition of CYP3A 
enzymes by furanocoumarin derivatives in grapefruit juice.[33] Also, a 
common flavoring agent, menthol, is shown to inhibit CYP2A6 resulting in 
decreased nicotine metabolism.[34,35] Smoking of mentholated cigarettes 
slows down the metabolism of nicotine resulting in higher systematic nicotine 
exposure compared to smoking of nonmentholated cigarettes. Humans are 
also exposed to wide variety of other chemicals and the metabolic effects are 
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not always very well known. In human liver microsomes (HLM), 
organophosphate pesticides inhibit CYP1A1/2 and CYP2B6, whereas 
pyrethroid insecticides showed inhibitory potential towards CYP2D6 and 
CYP3A4.[36] Parabens and phthalates commonly used in e.g., cosmetics and 
plastics, may have inhibitory effect on CYP enzymes as well.[37] Also, 
alterations in CYP activity are linked to nanomedicines, including viral vectors 
and silver and gold nanoparticles [38], which are emerging tools for targeted 
drug delivery in precision medicine.[39] 
 
Figure 2 Up: A schematic presentation of the different reversible enzyme inhibition 
mechanisms. S: substrate; I: inhibitor. Down: The effects of different inhibitor types 
on Lineveawer-Burk graphs. Red line: with inhibitor; green line: no inhibitor. 
1.1.3 SCREENING OF INDIVIDUAL DIFFERENCES IN ENZYME 
ACTIVITIES 
Screening of individual CYP activities before prescribing a treatment for a 
patient would be beneficial, especially in case of multiple medications or drugs 
with very narrow therapeutic window. The U.S. Food and Drug Administration 
(FDA) has added recommendations of CYP genotype testing and adjusted 
dosage in a set of product labels, including the anticoagulant warfarin with 
narrow therapeutic window and high risk of severe adverse effects.[40,41] 
Also, in case of unexpected drug responses, investigation of the CYP activities 
could provide explanation and help in adjusting the medication. 
Few different commercial tests for fast and simple determination of genetic 
polymorphism are available.[10,42] However, these are limited mainly to the 
most common variants of CYP2D6, CYP2C9, and CYP2C19, whereas rare 
variants will not be detected. Another disadvantage of these assays is that all 
the other sources of individual variation described in previous chapters are not 
considered. More complete information of the CYP activities can be obtained 
by administration of a probe drug that is metabolized by a single CYP enzyme. 
The ratio of the parent drug and its specific metabolite in urine, blood, or saliva 
is then monitored to determine the enzyme activities.[10,42] Administration 
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of the probe drugs in therapeutic doses may however result in adverse effects 
especially if multiple probes are used (cocktail assay) to investigate activity of 
more than just one CYP enzyme. In addition, these methods typically require 
frequent sampling for up to 8 hours, even though also new simple methods 
enabling single analysis of a dried blood spot are developed to facilitate the 
analysis of metabolic ratio.[43] In the future, individual alterations in CYP 
activities will most likely be considered also in terms of precision medicine. 
1.2 MICROFLUIDIC ANALYTICAL SYSTEMS
The first miniaturized separation device, a gas chromatograph, was developed 
more than 10 years before the introduction of the μTAS concept [44], but the 
real interest in microfluidic separation systems was not increased until 1990’s. 
Since then, many analytical separation techniques have been miniaturized to 
increase the throughput by faster analysis, integration of multiple operations, 
and parallelization. In addition, miniaturization results in decreased sample 
and solvent consumption and reduced costs. In the following chapters, 
miniaturization of capillary (zone) electrophoresis (CE) and liquid 
chromatography (LC) are prescribed, as these techniques are typically most 
suitable for analysis of (small molecule) pharmaceuticals. In addition, 
feasibility of microfluidic paper-based lateral flow assays for pharmaceutical 
applications are discussed. 
1.2.1 MICROCHIP ELECTROPHORESIS
In conventional CE, the sample is injected to a capillary filled with electrolyte 
solution and an electric field is applied across the capillary to create 
electroosmotic flow towards the detector in the other end of the capillary. The 
charged analytes are separated in the capillary based on their different 
electrophoretic mobilities (size and charge of the molecule). CE is a relatively 
simple technique and inherently suitable for miniaturization, and thus 
microchip electrophoresis (MCE) has become the most commonly 
miniaturized separation technique.[45] Also other electromigration 
techniques, including isoelectric focusing [46,47], isotacophoresis [48], 
micellar electrokinetic chromatography [49,50], electrochromatography [51], 
and gel electrophoresis [52,53], have been miniaturized. In this thesis, only 
miniaturization of capillary (zone) electrophoresis is discussed, as it is the 
most widely applied electromigration technique in analysis of pharmaceuticals 
and related small molecules. 
The separation principle of MCE is the same as in conventional CE, but in 
MCE the separation takes place in a microfabricated channel (few centimeters 
long, typically rectangular cross-section) instead of a round capillary (ca. 1 m 
long). A great benefit of MCE over conventional CE is the easy manipulation 
of very small volumes of fluids and especially the possibility to inject a very 
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narrow sample plug defined by the intersection of the microfabricated 
channels (Figure 3).[45,54] The narrow initial sample plug enables the use of 
short separation channels in MCE and thus much faster separation of the 
analytes compared to conventional CE. The sample can be injected 
electrokinetically from an injection channel to the separation channel 
resulting in reproducible injection in picoliter scale. The most common 
channel geometries include simple cross and offset (double-T) designs 
(Figure 3), where the sample flows across the separation channel as a result of 
electric field applied across the injection channel.[54] When the electric field 
is switched across the separation channel, the sample plug defined by the 
geometry of the injection cross, is introduced to the separation channel 
(floating injection, Figure 3).[55] The repeatability of the injection can be 
further increased by preventing sample leakage to the separation channel 
during the injection step by applying small focusing potential to buffer inlet 
and outlet (pinched injection, Figure 3). Similarly, small push-back voltages 
can be applied to the sample inlet and sample waste during the separation step 
to “push” the rest of the sample back to the injection channel. 
The first MCE devices were fabricated of glass by micromachining 
techniques adopted from semiconductor industry.[45,56,57] Glass has 
beneficial properties including optical transparency and thermal stability. In 
addition, it is very hard material and the surface can be easily modified based 
on the silane chemistry, but fabrication of glass devices requires cleanroom 
facilities and is relatively complex and expensive. 
 
Figure 3 Schematic view of typical MCE channel designs (left) and of applied voltages in 
floating and pinched injection modes during injection and separation steps (right).
The arrows show the direction of the liquid flow. BI: buffer inlet; BO: buffer outlet; SI:
sample inlet; SW: sample waste; gnd: ground. Injection channel from SI to SW, 
separation channel from BI to BO. Grey: sample; white: background electrolyte.
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Polymers have been investigated as alternative materials for microfluidic 
devices as they are generally cheaper and easier to fabricate, and thus better 
suitable for disposable devices.[56,58] In addition, a wide variety of polymers 
with different chemical, mechanical, and optical properties exist, which 
enables selection of the most suitable material for each application. The first 
polymer-based MCE device was fabricated of the elastomer 
polydimethylsiloxane (PDMS).[59] Currently, PDMS is the most commonly 
used microfabrication material in microfluidic research since it is inherently 
biocompatible and suitable for fast prototyping outside cleanroom 
conditions.[56] However, the hydrophobic surface is prone to nonspecific 
adsorption of analytes and thus surface modifications are needed before 
PDMS devices can be used for analytical purposes. Despite the wide use of 
PDMS in academic world, it is typically avoided in commercial devices as it is 
not very well suitable for large-scale fabrication.[56] Many other polymers are 
also investigated, including e.g., poly(methylmethacrylate) (PMMA) [60], 
polycarbonate [61], epoxy photoresist SU-8 [62], and thiol-enes [63,64], to 
overcome some of the limitations related to PDMS. The most important 
properties of the materials regarding MCE include inert surface chemistry to 
avoid nonspecific interactions and to maintain EOF. Depending on the 
detection method, also optical transmittance and clarity are often desired. 
Detection methods
In conventional separation systems, the most common detection methods for 
analysis of pharmaceuticals and related small molecules are ultraviolet (UV) 
absorbance, mass spectrometry (MS), fluorescence, and electrochemical (EC) 
detection. The first MCE systems were combined with laser induced 
fluorescence (LIF) as a detection method.[55,65–67] It is a sensitive method 
due to low background noise (especially on glass chips) and it is relatively easy 
to combine with the MCE system. Today, it is still very commonly used even 
though the detection itself is generally not miniaturized but requires bulky 
instrumentation e.g., microscopes, excitation sources, and photomultiplier 
tubes.[45,68] Few studies on miniaturization of fluorescence detection have 
been performed utilizing light emitting diodes (LED) as excitation source.[69–
71] The miniaturized detection system was combined with MCE and applied 
for analysis of endogenous biomarkers and pharmaceuticals from urine and 
plasma samples. However, the analytes required off-chip fluorescence 
labeling, which inevitably increases the analysis time and the manual work 
load. Most pharmaceuticals and related small molecules are not inherently 
fluorescent and require derivatization, which may complicate the process 
unless the fluorescence labeling is integrated on the same microchip. 
UV absorbance is widely used detection method in conventional 
bioanalytical systems, but in miniaturized systems the optical path length is 
typically very short, which decreases the sensitivity of absorbance detection 
significantly and thus its suitability for miniaturization.[72] Few devices with 
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e.g., integrated waveguides [73] or microlenses and detection cells with 
extended path length [74] exist for absorbance detection, but their use is 
limited to applications where high sensitivity is not required.[75] 
EC has been combined with MCE for almost as long as LIF [45], 
amperometric detection being the most commonly miniaturized and best 
suited electrochemical method for bioanalytical applications.[76] 
Amperometric detection is based on reduction and oxidation (redox) reactions 
of the analytes at the working electrode (WE) surface.[77] A constant potential 
is applied to the WE and the redox reactions are observed as changes in the 
current, which is proportional to the analyte concentration. Detection 
sensitivity of EC is not decreased by miniaturization, but the signal-to-noise 
ratio can even be improved as the surface-to-volume ratio (of the WE and 
sample) is typically higher in miniaturized systems.[77,78] Fabrication of the 
electrodes is relatively easy with common microfabrication techniques and the 
electrodes can be directly integrated to the microchip, which simplifies the 
operation of the device. EC is also more universal detection method than 
fluorescence, and the selectivity of the detection can be further adjusted by the 
choice of the electrode material.[77] Pharmaceuticals do often have easily 
oxidized functional groups enabling easy EC detection. In addition, EC 
detection does not require large additional instrumentation (like LIF) and 
portability is easily achieved.[77,78] 
In conventional bioanalysis mass spectrometry is a major detection method 
due to its high specificity, low detection limits, and quantitativity. Especially 
electrospray ionization (ESI) benefits from miniaturization.[79] The low flow 
rates in MCE enhances the production of smaller droplets, which in turn 
results in more efficient ionization and improved sensitivity. In addition, a 
sharp tip or nozzle is required to produce the spray. In the first miniaturized 
devices the spray was produced directly from a channel opening in the planar 
edge of the microchip.[80,81] The lack of sharp tip causes the sample to spread 
on the planar edge and high voltages were required to produce the spray. To 
overcome these challenges external nanospray emitters, e.g. silica capillaries 
or nanospray needles, were attached to the channel outlet to create a sharp 
nozzle.[82,83] However, the addition of external emitters increases manual 
work as well as dead volumes in the liquid junctions leading to peak 
broadening. Later, monolithically integrated sharp tips have been developed 
to avoid these issues.[84,85] The miniaturized ionization techniques are still 
mainly used with conventional, large, and expensive mass spectrometers, even 
though miniaturization of the entire instrument has also been 
investigated.[86] However, vacuum is required for efficient mass analysis, but 
if the vacuum pumps are miniaturized, their capacity will also be decreased, 
which is a limitation in developing completely miniaturized mass 
spectrometers. 
Introduction 
24 
Applications in pharmaceutical analysis
A wide range of MCE bioapplications have been published covering analysis of 
cells, cell components and lysates, DNA, proteins and peptides, and antibodies 
and antigens.[87] The applications in analysis of pharmaceuticals and related 
small molecules include analysis of pure drug compounds, active ingredients 
in pharmaceutical dosage forms, as well as drugs and/or their metabolites in 
biological matrices. Some applications in analysis of pharmaceuticals and 
related small molecules are listed in Table 1 sorted by the detection method. 
Generally, the reported limits of detection (LOD) and quantitation (LOQ) were 
in low micromolar level, but with mass spectrometric detection LODs from few 
nanomoles to tens of nanomoles per liter were achieved. The precision values 
of the MCE methods were also good, below 5% CV (coefficient of variation) in 
most cases. However, the concentrations used for determination of precision 
were often quite high and precision near LOD/LOQ was not generally 
reported. 
Despite the almost 30 years of MCE analysis and variety of published 
applications, the method has not reached an interest comparable to e.g., 
conventional LC. One of the biggest questions is the robustness of the method 
and only few validated quantitative methods exists. MCE may not be able to 
compete in sensitivity with conventional methods in the most challenging 
applications, but not all applications require extreme sensitivity and there 
MCE could be most useful. The limits of detection (LOD) and precision are 
determined in many applications, but further validation according to the 
guidelines of e.g., the FDA [88] or the ICH (International Conference on 
Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use) [89] is not commonly completed. As an 
example of further validation, a quantitative MCE method with fluorescence 
detection for analysis of diuretics both in tablets and in urine samples was 
developed. [90] The method was validated in terms of linearity, limits of 
detection (LOD) and quantitation (LOQ), precision of peak area and migration 
time and recovery (from tablets). LOQs of 2 μg/mL or below were achieved 
with intraday precisions below 2.30% (CV). 
Another challenge is the sample preparation. Many miniaturized on-chip 
sample preparation methods have been developed including e.g. solid-phase 
extraction [91–95], liquid-phase microextraction [96,97], and 
electromembrane extraction [98,99]. However, most of the MCE methods and 
applications still rely on off-chip (manual) sample preparation before the 
separation on chip with few exceptions of on-chip sample processing. An 
integrated labeling protocol was demonstrated in quantitative analysis of four 
thiol drugs with chemiluminescence detection, but the analysis of the drugs in 
plasma samples still required additional off-chip sample clean-up.[100] Also, 
an on-chip liquid-phase microextraction utilizing a porous membrane has 
been demonstrated in analysis of two painkillers, tramadol and paracetamol, 
and their metabolites in urine samples.[96] 
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1.2.2 MICROCHIP LIQUID CHROMATOGRAPHY
Liquid chromatography (LC) is the most commonly used conventional 
separation technique in bioanalysis. The sample is injected to a liquid (mobile 
phase) which is pumped (pressure-driven flow) through a column packed with 
stationary phase. The analytes are separated based on their different 
interactions (retention) with the stationary phase. LC is suitable for analysis 
of a large variety of compounds as the methods can be adjusted by selecting 
appropriate stationary phase and mobile phase composition. 
Microchip LC (from now on chipLC) is especially advantageous in 
applications with limited sample volume, where the miniaturization reduces 
dilution of the sample in the column and thus results in enhanced 
sensitivity.[109] ChipLC also enables development of portable 
instrumentation for e.g., on-site analysis or point-of-care diagnostics, and 
reduces solvent consumption and analysis time. However, implementation of 
LC on a microchip has not gained as much attention as MCE. 
The main challenge in chipLC is the channel structure. In MCE a simple 
microchannel is needed for separation, which is relatively easy to fabricate. 
Instead, chipLC requires a more complex structure, as the stationary phase 
needs to be integrated in the channel. It can be integrated manually by adding 
small particles and frits to the channel [110], by adding a monolithic structure 
[111,112], or by fabricating microstructures, e.g. pillars [113,114], 
simultaneously with the channel.[115] 
Another significant difference is the liquid handling as chipLC utilizes 
pressure-driven flow instead of electrokinetic flow. In chipLC a very precise 
and stable liquid flow with flow rates between nanoliters per minute to few 
microliters per minute is required while the operating pressures are around 
700 bars or even higher.[115] Electroosmotic flow can, however, be utilized to 
create pressure-driven flow in non-mechanical pumps.[116–118] These 
electroosmotic pumps are relatively easy to fabricate and integrate as on-chip 
pumps, because they don’t include any moving parts.[115,116] Also, a 
continuous pulse-free flow can be created and the direction of the flow can 
easily be changed by switching the polarity of the electric field. Other non-
mechanical pumps include electrochemical [119,120], electrohydrodynamic 
[121], and magnetohydrodynamic pumps [122,123]. However, currently most 
chipLC systems utilize external mechanical off-chip pumps connected to the 
actual microchip, commonly either reciprocating pumps or syringe 
pumps.[115] The challenge in these systems is the dead volumes in liquid 
junctions of the connecting capillaries between pumps and the actual 
microchip: as the total volume in the system decreases, the proportion of the 
dead volume increases correspondingly causing peak broadening.[115,124] 
The low interest in development of chipLC may also be at least partly related 
to the fact, that commercial LC systems with decreased column, sample, and 
detection volumes (capillary and nano LC) already have some of the benefits 
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of miniaturization, including smaller solvent consumption and enhanced 
sensitivity.[115,124,125] However, the relatively large dead volumes in liquid 
junctions are a challenge also in these systems. 
The first chipLC devices were prepared of silicon, but as it is not optically 
transparent in UV or visible light, it was replaced by glass-based devices.[115] 
In chipLC the system needs to stand high pressures, which limits the use of 
some polymers, especially PDMS.[56] Thermoplastics, including PMMA, 
polystyrene, are transparent and more rigid materials and thus better suitable 
for chipLC. However, many polymers suffer from poor solvent compatibility, 
which limits their use in chipLC, as organic solvents are commonly used in 
mobile phases.[58] Cyclic-olefin copolymer is an example of a hard and 
transparent material, which is also more tolerant to organic solvents.[115] 
Optical detection, EC detection and mass spectrometry are the most 
common detection methods also for chipLC.[115] Fluorescence detection is the 
main optical method, but as described also in case of MCE, inherent 
fluorescence is not very common phenomena. Commercial vendors have been 
especially interested in developing instrumentation for integration of chipLC 
and MS.[115,126–129] Similarly as in the case of MCE, the chipLC is typically 
integrated with conventional large scale mass spectrometers disabling 
portability or analysis in the field. The high sensitivity of MS, however, enables 
analysis of very small amounts of the analytes. For example, a chipLC-MS/MS 
method was able to detect a set of abused drugs and their metabolites in 
human hair samples with limits of detection between 0.1 and 0.75 pg/mg hair 
and limits of quantitation between 0.2 and 1.25 pg/mg hair.[130] In another 
application, antidepressant fluoxetine and its metabolite norfluoxetine were 
analyzed from only 20 μL of rat serum by a chipLC-MS/MS method with LODs 
of 0.18–0.67 ng/mL.[131] Most likely the chipLC could benefit the field of drug 
discovery by enabling fast analysis of small sample volumes in laboratory 
conditions instead of on-field or point-of-care analysis. 
1.2.3 PAPER MICROFLUIDICS
The concept of microfluidic paper-based devices (μPADs) was introduced in 
2007 [132] following the principles of paper chromatography and lateral flow 
diagnostic assays (e.g. pregnancy tests) that have existed far longer.[133,134] 
Medical diagnostics and point-of-care/in-field analysis have been the main 
application areas of μPADs due to their special properties enabling simple and 
fast analysis.[135,136] A lot of applications of these disposable low-cost 
devices have been investigated for the needs of developing countries or 
resource-limited areas, where other laboratory equipment may not be easily 
accessible. Also applications in environmental and food safety monitoring 
have gained lot of attention.[134,135] 
μPADs are typically implemented on a cellulose substrate, which provides 
unique properties compared to traditional microfabricated devices described 
in the previous chapters.[135] Cellulose is abundant, inexpensive, lightweight, 
Introduction 
28 
and biodegradable, and as a hydrophilic porous material it enables fluid flow 
generated by capillary action without any external pumps or power supplies. 
Another attractive aspect is the easy fabrication of these devices. 
Hydrophobic areas are created to form liquid barriers and to control the fluid 
flow on the μPAD. A variety of deposition techniques exist (Figure 4) [137] and 
wax printing (Figure 4G) with standard office printer is one of the most 
commonly adopted methods.[134,135] After printing, the wax is melted 
through the porous cellulose-based substrate to create the channel walls. The 
development of new hydrophobic agents (e.g. alkyl ketene dimer, AKD) has 
increased the use of inkjet printing (Figure 4I), which enable fast and low-cost 
deposition with relatively high throughput and reproducibility.[134] In 
addition, the design of the channel structure can be easily modified and the 
new version of the device can be printed on demand. 
 
Figure 4 A schematic of different fabrication techniques of paper-based microfluidic devices. 
Hand crafted devices (top) can be fabricated by (A) wax drawing, (B) polymer ink 
drawing/stamping, or (C) wax stamping. Hydrophilic regions are protected with masks 
(left) in (D) wax dipping, (E) photolithography, and (F) wax screen-printing 
techniques. Printing techniques (bottom) include (G) wax printing, (H) inkjet etching, 
(I) inkjet printing, and (J) flexographic printing. For cutting and shaping air boundaries 
or etching channels, (K) a craft cutter or (L) a laser cutter can be used. Color codes: 
yellow: hydrophobic polymer; black: wax; grey: melted wax; blue: mask. Reprinted 
from ref. [134] with permission from ACS Journals.  
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Detection in μPADs is typically based on colorimetric methods.[134,135,138] 
It provides easy and simple readout without any additional instrumentation 
and is thus very easily suitable for point-of-care and in-field applications. 
Colorimetric methods are based on either simple yes/no answer or a set of 
multiple color reactions that are specific for a compound or a functional group 
in the structure. The latter approach can enable even identification of a 
compound. However, the sensitivity is not very good and for quantitative 
analysis, additional instrumentation is usually needed.[135] The worldwide 
distribution of smartphones has enabled a new approach, called 
“telemedicine”.[139] Using a smartphone, a photo of the μPAD (after 
colorimetric reaction) can be send to a doctor or to a research laboratory for 
interpretation of the results. Also smartphone applications for result 
interpretation have been developed. EC detection can also be integrated to 
μPADs, in this case also called ePADs (electrochemical paper-based analytical 
devices), with relatively simple and low-cost methods.[140] The clear 
advantages of EC detection over colorimetric detection are the better 
sensitivity, selectivity, and quantitativity [135,140,141], while additional 
instrumentation is necessary. 
In addition to the applications in medical diagnostics, only few spot-on 
tests for pharmaceutical applications have been developed. Screening of illegal 
drugs [142,143] and counterfeit or low quality pharmaceuticals [144–147] with 
a simple μPAD, has aroused interest, as no skilled personnel or laboratory 
equipment is needed. For example, a μPAD was developed for simultaneous 
detection and identification of multiple abused and illegal drugs, including 
opiates, phenethyl amines, cocaine, and ketamine (Figure 5, left).[142] The 
device consisted of 6 channels, with one or more colorimetric reagents in each. 
With combinations of the different reactions, each of the nine drugs could be 
detected and distinguished from each other based on the produced colors. Also 
semiquantitative analysis could be performed with smartphone and an image 
processing software. In another example, a quantitative colorimetric 
immunosorbent assay for analysis of ketamine in saliva was able to reach 
detection limit of 0.03 ng/mL. [143] However, the procedure included manual 
application of multiple reagents and additional heating and washing steps, 
decreasing the suitability for in-field analysis by non-experienced persons. In 
search of counterfeit or low quality pharmaceuticals, focus has been on β-
lactam antibiotics [144,145] and antimalarial drugs [146,147], most likely due 
to their wide use in resource-limited areas. For example, a “β-lactam PAD” was 
developed for easy confirmation of the active ingredients in tablets.[144] The 
solid tablet was “swiped” across the device (Figure 5, right) and the PAD was 
then dipped in water to initiate the analysis. Based on a “color bar code” 
created from the 12 parallel lines with different reactants, the different β-
lactam antibiotics could be identified. In addition, the μPAD was able to detect 
common excipients (e.g. starch) as well as “substitute” active ingredients that 
are typically used in falsified drugs. 
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Figure 5 Examples of μPADs based on colorimetric detection. Left: μPADs for detection of 
abused and illicit drugs. Top: analysis of blank sample; Bottom: analysis of morphine 
(positive result). Each channel is labelled with the abbreviation of the analytes 
detected and the color of the text shows the color produced in the case of positive 
result. Eph; ephedrine; MA: methamphetamine; MDMA: 3,4-methylenedioxide-
methamphetamine (ecstasy); Coc: cocaine; Ket: ketamine; Cod: codeine; Theb: 
thebaine; Morph: morphine; Amp; amphetamine. Reproduced from ref. [142] with 
permission form Royal Society of Chemistry. Right: μPADs for screening of β-lactam 
antibiotics based on a color bar code. The studied tablet is “swiped” across the lines 
A-L. (a) 100% amoxicillin gives dark green in lane A, green in lane B, and orange in 
lane G. (b) A 2:1 w/w mixture of ampicillin and calcium carbonate gives blue-green in 
lane A, orange in lane B, and no color in lane G (indicating ampicillin rather than 
amoxicillin) and dark orange at the swipe line in lanes I and J (indicating carbonate). 
(c) Maize flour gives no API colors and dark purple at the swipe line in lane H 
(indicating starch). Adapted from ref [144] with permission from ACS Journals. 
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2 AIMS OF THE STUDY
The overall aim of the study was to evaluate the feasibility of microfluidic 
analytical methods for pharmaceutical research. Also, emphasis was put on 
drug metabolism research and precision medicine. 
The microfluidic analytical techniques were evaluated in different types of 
pharmaceutical applications, including both quantitative and qualitative 
analysis by simple commercial devices as well as customized techniques. 
Sensitivity and robustness required for different applications were also 
evaluated. Drug metabolism was studied with a view to precision medicine by 
evaluating the effects of nanocarriers on CYP metabolism. One of the aims was 
also to develop a microfluidic method for screening of individual CYP activities 
as a tool for precision medicine. 
 
The more detailed aims were 
 to study the effects of porous silicon (PSi) nanoparticles and 
polymers commonly used in the same pharmaceutical 
nanoformulations on CYP enzyme activities and clearance 
 to assess the need to examine the metabolic effects of nanocarriers 
as a part of toxicity and biocompatibility assessment 
 to evaluate the suitability of a μPAD for screening of individual 
differences in metabolic activities of CYP enzymes 
 to study the feasibility of a commercial MCE-EC device for 
quantitative analysis of targeted compounds in biological samples 
and for rapid analysis of CYP enzyme activities 
 to assess the applicability of the above mentioned MCE-EC 
methodology for routine use in site of research, e.g. in animal 
laboratory 
 to evaluate the power of MCE in challenging analytical tasks by 
developing an MCE-ESI/MS method for separation of phospho-
peptides including separation phosphorylation isomers 
Experimental 
32 
3 EXPERIMENTAL
This section briefly describes the chemicals, materials, instruments and 
protocols used in the study. Details are provided in the original publications 
(I–IV). 
3.1 CHEMICALS AND MATERIALS
Chemicals and materials used in this work are listed in Table 2. The notes 
indicate their use. The CYP probe substrates and corresponding metabolites 
are listed in Table 3. 
Table 2. Chemicals and materials used in the study.
Chemical/Material Manufacturer/Supplier Note Publication
2-(N-morpholino)-ethanesulfonic 
acid (MES) hydrate
Sigma-Aldrich, Steinheim, 
Germany
Reagent II, III
2-Propanol Sigma-Aldrich, Steinheim, 
Germany
Solvent III
9-Fluorenylmethyl chloroformate 
(Fmoc-Cl)
Sigma-Aldrich, Steinheim, 
Germany
Derivatization 
reagent
IV
9-Fluorenylmethyl N-succinimidyl 
carbonate (Fmoc-OSu)
Sigma-Aldrich, Steinheim, 
Germany
Derivatization 
reagent
IV
Acetic acid Sigma-Aldrich, Steinheim, 
Germany
Reagent IV
Acetonitrile Sigma-Aldrich, Steinheim, 
Germany
Solvent I, II, IV
Ammonium acetate Sigma-Aldrich, Steinheim, 
Germany
Reagent IV
Ammonium sulfate Riedel-de Haën, Seelze, 
Germany
Reagent III
β-nicotinamide adenine 
dinucleotide 2’-phosphate reduced 
tetrasodium salt hydrate (NADPH)
Sigma-Aldrich, Steinheim, 
Germany
Cosubstrate I, II
Boric acid Riedel-de Haën, Seelze, 
Germany
Reagent II–IV
Chloroform Sigma-Aldrich, Steinheim, 
Germany
Solvent III
Dipotassium hydrogenphosphate Amresco, Solon, OH, USA Reagent I, II
Formic acid Sigma-Aldrich, Steinheim, 
Germany
Reagent I, IV
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(Table 2 continues)
Chemical/Material Manufacturer/Supplier Note Publication
Human liver microsomes (HLM), 
pooled from 20 donors 
Corning, Wiesbaden, 
Germany
Enzyme 
product
I, II
Human liver microsomes (HLM), 
single donor
Corning, Wiesbaden, 
Germany
Enzyme 
product
II
Insulin receptor peptide (1142–
1153), nonphosphorylated (IR0)a
Anaspec, Fremont, CA, USA Standard IV
Insulin receptor peptide, 
monophosphorylated (IR1A)a
Anaspec, Fremont, CA, USA Standard IV
Insulin receptor peptide, 
monophosphorylated (IR1B)a
Anaspec, Fremont, CA, USA Standard IV
Insulin receptor peptide, triply 
phosphorylated (IR3)a
Anaspec, Fremont, CA, USA Standard IV
Magnesium chloride hexahydrate Sigma-Aldrich, Steinheim, 
Germany
Reagent I, II
Methanol Sigma-Aldrich, Steinheim, 
Germany
Solvent I, IV
Morphine hydrochloride University Pharmacy, Helsinki, 
Finland
Standard III
Perchloric acid Riedel-de Haën, Seelze, 
Germany
Reagent I, II
Potassium dihydrogenphosphate Riedel-de Haën, Seelze, 
Germany
Reagent I, II
Sodium phosphate dibasic 
dihydrate
Sigma-Aldrich, Steinheim, 
Germany
Reagent III
Sodium phosphate monobasic 
dihydrate
Sigma-Aldrich, Steinheim, 
Germany
Reagent III
Trizma® base Sigma-Aldrich, Steinheim, 
Germany
Reagent I, II
Water (Milli-Q) Millipore, Molsheim, France Solvent I–IV
a IR0: TRDIYETDYYRK; IR1A: TRDIpYETDYYRK; IR1B: TRDIYETDpYYRK; IR3: TRDIpYETDpYpYRK;
T: threonine; R: arginine; D: aspartic acid; I: isoleucine; Y: tyrosine; E: glutamic acid; K: lysine; p:
phosphorylated amino acid  
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Table 3. CYP probe substrates, metabolites, and specific inhibitors. The probes
recommended by the FDA [148] are written in italics.
Enzyme Substrate Metabolite Publication
CYP1A2 Phenacetin Paracetamol I
3-Cyano-7-ethoxycoumarin 
(CEC)
3-Cyanoumbelliferone (CHC) II
CYP2A6 Coumarin Umbelliferone I, II
CYP2B6 7-Methoxy-4-trifluoro-
methylcoumarin (7-MFC)
7-Hydroxy-4-trifluoro-
methylcoumarin (7-HFC)
II
CYP2C19 7-Methoxy-4-trifluoromethyl-
coumarin (7-MFC)
7-Hydroxy-4-trifluoromethyl-
coumarin (7-HFC)
II
CYP2D6 Bufuralol 1’-Hydroxybufuralol I
Luciferin-ME EGE Luciferin-EGEa I
AMMC AMHC II
CYP2E1 7-Methoxy-4-trifluoromethyl-
coumarin (7-MFC)
7-Hydroxy-4-trifluoromethyl-
coumarin (7-HFC)
II
CYP3A4 Testosteroneb 6β-Hydroxytestosterone I
7-Benzyloxyresorufin Resorufin II
Dibenzylfluorescein Fluorescein II
a D-Luciferin is formed after deesterification of Luciferin-EGE by the esterase included in the Luciferin 
detection reagent of P450-Glo™ CYP2D6 Assay Kit (Promega). 
b FDA recommends that two different substrates that are not structurally related are used for studying 
CYP3A4 inhibition. 
ME: methyl ether; EGE: ethylene glycol ether; AMMC: 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-
7-methoxy-4-methylcoumarin; AMHC: 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-hydroxy-4-
methylcoumarin; N/A: not applicable. 
3.2 SAMPLE PREPARATION
3.2.1 ENZYME INCUBATIONS
The CYP probe reactions recommended by FDA (Table 3) and a validated LC-
MS method were used to study the effects of nanoformulations on the enzyme 
activities and clearances (I). The dose-dependent inhibition of CYP2D6 by the 
nanoparticles was further investigated using luciferin-based probe reaction. 
The fluorogenic CYP substrates were used in study of individual differences in 
enzyme activities (II). 
The incubation conditions for CYP model reactions in liquid phase are 
listed in Table 4. The probe substrates were diluted in the incubation buffer, 
except for testosterone (5% (V/V) methanol left in reaction mixture) and CEC 
(2% (V/V) acetonitrile left in reaction mixture), which did not dissolve in 
purely aqueous solution. The substrate and the HLM were preincubated at 
37 °C for 5 min before initiating the reaction by the addition of NADPH (1 mM 
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in reaction). The reaction mixture was incubated at 37 °C for the specified time 
after which the reaction was terminated by adding the quenching solution. The 
samples (except luminescence-based reactions) were placed on ice for at least 
10 min after which the precipitated HLM was removed by centrifugation 
(16,000 g, 10 min) and the supernatant was collected for analysis. The 
luminescence-based samples were allowed to stand still in room temperature 
until measurement 20 min after addition of the quenching solution. The 
enzymatic reactions were performed in a total volume of 100 μL. Samples were 
analyzed without further sample treatment by LC-MS (I), luminescence (I), or 
fluorescence (II) depending on the metabolite. 
Effects of nanoparticles and polymers
The enzyme kinetic parameters were determined for four CYP enzymes, 
CYP3A4, CYP2D6, CYP1A2, and CYP2A6, with testosterone, bufuralol, 
phenacetin, and coumarin as probe substrates, respectively (I). The enzyme 
activities (Vmax), the Michaelis constants (Km), and the intrinsic clearances 
(CLint) were compared in the presence of three types of PSi nanoparticles and 
without them. The studied nanoparticles were alkyne-terminated thermally 
hydrocarbonized PSi (Alkyne-THCPSi), aminopropylsilane-modified 
thermally carbonized PSi (APTES-TCPSi), and thermally carbonized PSi 
(TCPSi). The reactions were performed as described above with seven 
different substrate concentrations. The nanoparticles (1 mg/mL in reaction) 
were added to the reaction mixture before preincubation step, and removed 
after the reaction together with the precipitated HLM by centrifugation. The 
effect of nanoparticle dose on CYP2D6 activity was studied using Luciferin-
ME EGE as substrate. Seven different concentrations (1 ng/mL–1 mg/mL) of 
each type of nanoparticles were compared to control samples without 
nanoparticles. Comparison of the enzyme kinetic parameters in the presence 
of three polymers (0.1% m/V in reaction) was conducted similarly as with the 
nanoparticles. The selected polymers, Pluronics F68 and F127, and polyvinyl 
alcohol (PVA), are commonly used in the nanoformulations together with the 
PSi nanoparticles. 
Incubations of the substrates and metabolites (one concentration) with 
each nanoparticle type were also performed without enzymes to distinguish 
the adsorption from enzyme inhibition. To study the adsorption effects in 
more detail, bufuralol and 1’-hydroxybufuralol were incubated with each 
nanoparticle type with different concentrations. Similarly, testosterone and 
6β-hydroxytestosterone were studied in more detail in the presence of Alkyne-
THCPSi. The observed free fractions were taken into account in calculating the 
enzyme kinetic parameters. 
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Table 4.
Incubation conditions for C
YP
 m
odel reactions.
C
YP1A
2
C
YP2A
6
C
YP2D
6
C
YP3A
4
Substrate
Phenacetin
C
EC
C
oum
arin
 
Bufuralol
Luciferin-M
E EG
E
 
Testosterone
M
etabolite
Paracetam
ol
C
H
C
U
m
belliferone
 
1’-O
H
-bufuralol
Luciferin-EG
E
 
6β-O
H
-testosterone
R
eaction in solution
Buffer
Phosphate
Tris
Tris
Phosphate
Phosphate
Phosphate
Enzym
e
0.8 m
g/m
L
0.8 m
g/m
L
0.4 m
g/m
L
0.8 m
g/m
L
0.4 m
g/m
L
0.5 m
g/m
L
Tim
e
20 m
in
20 m
in
15 m
in
20 m
in
30 m
in
10 m
in
Q
uenching
Perchloric acid
AC
N
Perchloric
acid
Perchloric acid
Luciferin detection reagent
Perchloric acid
Ex/em
N
/A
413/454 nm
355/447 nm
N
/A
N
/A
N
/A
Reaction on μPAD
Buffer
N
/A
Tris
Tris
N
/A
N
/A
N
/A
Enzym
e
N
/A
30 μg
30 μg
N
/A
N
/A
N
/A
Tim
e
N
/A
30 m
in
30 m
in
N
/A
N
/A
N
/A
Ex/em
N
/A
428/463 nm
367/447 nm
N
/A
N
/A
N
/A
C
EC
: 3-C
yano-7-ethoxycoum
arin; C
H
C
: 3-C
yanoum
belliferone; Phosphate: 0.1 M
 Potassium
 phosphate buffer (pH
 7.4) w
ith 3.3 m
M
 M
gC
l2 ; Tris: 0.1 M
 Tris buffer (pH
 7.5) 
w
ith 3.3 m
M
 M
gC
l2 ; Perchloric acid: 10%
 of reaction volum
e ice-cold 4 M
 perchloric acid is added to term
inate the reaction; AC
N
: Equal volum
e (100%
 of reaction volum
e) 
of acetonitrile is added to term
inate the reaction; Luciferin detection reagent: Equal volum
e (100%
 of reaction volum
e) of Luciferin detection reagent w
ith esterase (Prom
ega) 
w
as added to term
inate the C
YP m
ediated reaction and to catalyze the deesterification of luciferin-EG
E to D
-luciferin; Ex/em
: E
xcitation/em
ission m
axim
a; N
/A: N
ot applicable.
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3.2.2 PRETREATMENT OF PLASMA AND BRAIN SAMPLES
An MCE-EC method was developed and applied to analysis of morphine in 
mouse plasma and brain homogenate samples (III). The mice were 
administered 20 mg/kg morphine hydrochloride intraperitoneally (i.p.). After 
30 min, the mice were sacrificed and the trunk bood was collected. The brains 
were dissected and homogenized in 5 mL of ice-cold water. 
The samples were treated with liquid-liquid extraction (LLE) adopted with 
modifications from a previous study.[149] First saturated ammonium sulfate 
solution was added slowly to the sample and the mixture was centrifuged. The 
supernatant was collected and mixed with 0.1 M Na2HPO4 (pH 8.9) after 
which the mixture was extracted with chloroform–isopropanol (9:1) by vortex 
mixing. The organic phase was collected and the extraction was repeated. 
Finally, the organic phase was evaporated to dryness and the residue was 
dissolved in 5 mM MES buffer (pH 6.0) upon heating at 37 °C. The extraction 
resulted in 2-fold enrichment of plasma samples and 16-fold enrichment of 
brain homogenate samples. 
3.2.3 DERIVATIZATION OF PHOSPHOPEPTIDES
An MCE-ESI/MS method was developed for separation of phosphorylated 
peptides according to the number of phosphorylated amino acid residues. To 
enable separation of the two monophosphorylated peptide isomers (IR1A and 
IR1B), two different derivatization protocols were used with either 9-
fluorenylmethyl chloroformate (Fmoc-Cl) or 9-fluorenylmethyl N-
succinimidyl carbonate (Fmoc-OSu) as the derivatization reagent. Fmoc-Cl 
was used in stoichiometric ratio or in 5 or 10-fold molar excess relative to the 
free amino residues of the peptide. Reactions were performed by mixing 20 μL 
of Fmoc-Cl (in ACN) with 10 μL of 18 mM sodium borate (pH 10.0) and 10 μL 
of peptide stock solution (1 mM in Milli-Q water). The mixtures were vortexed 
for 1 min and the reactions were left to proceed at room temperature for 2 min, 
5 min, or 10 min. Fmoc-OSu was used in 10-fold molar excess and the 
reactions were initiated by mixing 10 μL of Fmoc-OSu (in ACN) with 10 μL of 
18 mM sodium borate (pH 10.0) and 20 μL of peptide stock solution (1 mM in 
Milli-Q water). The reactions were left to proceed at room temperature 
overnight. After specified reaction time, the reaction mixtures were diluted for 
analysis. 
3.3 ANALYTICAL METHODS
The most important instruments used in the study are listed in Table 5. Notes 
indicate their use. 
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Table 5. Instruments used in the study.
Instrument (model) Manufacturer/supplier Note Publication
High voltage power supply and 
bipotentiostat (HVStat)
MicruX Technologies, 
Oviedo, Spain
MCE-EC control III
Hybrid glass/SU-8 microchips 
(Pt-001T)
MicruX Technologies, 
Oviedo, Spain
Microchip for 
MCE-EC
III
Hybrid glass/SU-8 microchips 
(custom-designed)
MicruX Technologies, 
Oviedo, Spain
Microchip for 
MCE-EC
III
Ion trap mass spectrometer 
(6330)
Agilent Technologies, 
Santa Clara, CA,USA
Mass analysis IV
Liquid chromatograph 
(ACQUITY UPLCTM)
Waters, Milford, MA, USA Sample 
separation
I
Power supply Micralyne, Edmonton, 
Canada
MCE voltage 
supply
IV
Q-TOF mass spectrometer 
(Xevo)
Waters, Manchester, UK Mass analysis I
Varioskan Flash Multimode 
Reader
Thermo Fisher Scientific, 
Rockford, IL, USA
UV, luminescence I
Varioskan Lux Multimode 
Reader
Thermo Fisher Scientific, 
Rockford, IL, USA
Fluorescence II
3.3.1 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
LC-MS measurements in publication I were performed with electrospray 
ionization in positive ion mode using an ACQUITY UPLC™ chromatograph 
and a Xevo Q-TOF mass spectrometer. The detailed LC-MS parameters are 
given in the supplement of publication I. The analytical method was validated 
for specificity, linearity, limits of detection and quantitation, and repeatability 
according to the ICH guidelines.[89]
3.3.2 MICROFLUIDIC PAPER-BASED DEVICE
A microfluidic paper-based assay was applied to analysis of individual CYP 
enzyme activities. The μPAD platforms were fabricated similarly as described 
previously in references [150] and [151]. Briefly, the functionalized calcium 
carbonate (FCC) with microfibrillated cellulose as a binder was applied on top 
of a polypropylene sheet to form a ca. 140 μm thick coating. Two layers of AKD 
ink mixed with yellow dye (wood stain colorant 157) was printed to create 
hydrophobic walls defining the main design. A semipermeable barrier was 
created by printing 4 layers of polystyrene mixed with red dye (Sudan Red G). 
The assay design consists of different zones for each step of the protocol 
(Figure 6): The enzyme incubation is performed in the reaction area which is 
separated from the separation channel by the semibarrier which prevents 
leakage of the reaction mixture to the channel during the incubation. After the 
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incubation is completed, the reaction products are eluted through the 
semibarrier to the separation channel and finally to the tip where the 
fluorescent products can be detected. In addition, the assay includes the buffer 
reservoir area where an adsorbent pad is added during the incubation step to 
ensure that the reaction area stays wet. The multiplexed assay consists of 24 
parallel assays and is designed to be compatible with a conventional well-plate 
reader. For fluorescence measurement, the μPAD platform was attached 
directly on top of the 384-plate adapter of the well-plate reader and aligned 
with help of light from below so that each tip of the platform was in the middle 
of a well. 
 
Figure 6 The FCC platform used in the study. Left: single assay and the different operational 
zones. Right: The multiplexed platform with 24 parallel assays. 
Optimization of elution and detection 
The retention factors (Rf) were determined by applying high concentrations of 
the metabolite standards or NADPH to the reaction spots and let dry for 
15 min. The samples were eluted with elution buffer. The elution volumes were 
varied between 25 and 60 μL. An hour after elution, the assay was examined 
under UV lamp and the elution distance and band width were measured. To 
determine the optimal time point for detection, the metabolite standards were 
applied to the reaction areas and eluted as above. The fluorescence signals 
were measured every 10 min after elution up to 70–180 min and then with 
longer time intervals up to even 48 hours. The measurement was performed 
both at room temperature for the whole time and at 37 °C for first 6 hours and 
then at room temperature for the rest of the time. The LODs were roughly 
estimated by applying small amounts of each metabolite on a ring pattern (a 
circle with hydrophobic edges, detection without elution) and by measuring 
the fluorescence signals. The signals were compared to background signal to 
roughly estimate the LOD. 
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Enzyme incubations on-chip 
The enzyme incubations on the μPAD were performed either at room 
temperature or at 37 °C. In the latter case, the μPAD assay platform was 
prewarmed on a hot plate to 37 °C. First, 1.5 μL of a mixture containing both 
the substrate and the cosubstrate (NADPH) in 0.1 M Tris buffer (pH 7.5) 
including 3.3 mM MgCl2 was applied to the reaction area and let dry for ca. 
5 min. The adsorbent pad was prewetted in the same incubation buffer and 
placed on the buffer reservoir area. When the liquid front reached the edge of 
the reaction area, 1.5 μL of HLM solution (20 mg/mL) was added to the 
reaction area. The addition of the enzyme was considered as the starting point 
of the reaction. During the incubation, more buffer was added to the adsorbent 
pad if necessary to keep the reaction area wet. After the specified incubation 
time, the adsorbent pad was removed and the assay was let dry for 15 min 
before elution with 60 μL of 20 mM borate buffer (pH 10). The fluorescence 
signals were measured after the assay was completely dry. The incubation 
conditions were optimized in terms of incubation time and amount of NADPH. 
3.3.3 MICROCHIP ELECTROPHORESIS 
Microchip electrophoresis (MCE) was used for analysis CYP substrates and 
metabolites [152], morphine in mouse plasma and brain samples (III), and 
phosphopeptides (IV). The designs of the different microchips are presented 
in Figure 7. 
 
Figure 7 Schematic drawings (not in scale) and photographs of the microchips used in the 
study. Left: SU-8 microchip with ESI tip. Right: glass/SU-8 hybrid chips with straight 
and meandering separation channels. The platinum electrodes for amperometric 
detection are shown in the insert of the sketch. BI: buffer inlet; BO: buffer outlet; SI: 
sample inlet; SW: sample waste; SLI: sheath liquid inlet; WE: working electrode; RE: 
reference electrode; AE: auxiliary electrode. 
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Microchip electrophoresis-electrochemical detection
The commercial MCE-EC device (MicruX Technologies, Oviedo, Spain) 
consists of a high voltage power supply, a bipotentiostat, the hybrid 
glass/SU-8 microchip (Figure 7) with electrodes for EC detection, and a 
microchip holder with all necessary electrical connectors for applying the MCE 
and EC voltages. The channel cross-section of both injection and separation 
channel were 50 μm × 20 μm (width × height). The injection channel was 
10 mm long, whereas the injection channel geometry and the length of the 
separation channel depend on the chip design. The three thin-film platinum 
electrodes were located in the buffer outlet close to the channel end with 
100 μm spacing. The width of the working electrode (WE) was 50 μm, and the 
auxiliary electrode (AE) and the reference electrode (RE) were 250 μm wide 
each. 
Before use, the microchip was filled and rinsed with background electrolyte 
(BGE). The samples were loaded electrokinetically (floating injection) by 
applying electric field between the sample inlet and the sample outlet 
(Figure 7). The electrophoretic separation was performed by applying an 
electric field between the buffer inlet and the buffer outlet. The electrophoretic 
and electrochemical detection voltages were controlled by the HVStat software 
provided together with the instrument. 
For analysis of CYP metabolites, a custom-designed microchip (MicruX 
Technologies) with meandering separation channel (effective separation 
length, Leff 50 mm) and off-set (50 μm) injection layout was used 
(Figure 7).[152] The BGE composition, WE potential, and sample loading time 
were optimized for best sensitivity. 20 mM borate buffer (pH 10.0) was 
selected as BGE for analysis of paracetamol, whereas 20 mM MES buffer 
(pH 6.0) was used for umbelliferone. Optimal WE potential was 1 V for both 
metabolites. LOD, LOQ, selectivity, linearity, run-to-run precision, and day-
to-day precision was determined for both paracetamol and umbelliferone in 
optimized conditions. To increase the sensitivity, the paracetamol was diluted 
in 10 mM buffer (compared to 20 mM in BGE) and injected directly to the 
separation channel (electric field between SI and BO) followed by sample 
stacking during the separation step. The volume of the sample plug injected to 
the separation channel depends on the loading time, which was varied 
between 10 and 40 s. 
Analysis of morphine samples (III) was performed with a standard 
commercial microchip with straight separation channel (Leff 30 mm) and 
simple injection cross (Figure 7). 20 mM MES buffer (pH 6.5) was selected as 
the BGE, whereas the samples were diluted in 5 mM MES buffer (pH 6.0) 
which enabled additional concentration of the analytes by electrokinetic 
stacking during the separation step. The BGE composition, the separation 
voltage, and the WE potential were optimized for best selectivity and 
sensitivity. The robustness of the method was determined in terms of the 
loading time and the sample volume applied to the sample inlet. The method 
details are described in publication III. The method qualification was 
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performed by adopting the FDA Guidance for Industry – Bioanalytical Method 
Validation in relevant parts.[153] Lower limit of morphine quantitation 
(LLOQ), calibration curve, and between-run precision were determined with 
morphine standards in MES buffer. Selectivity, within-run precision, 
accuracy, and recovery were determined using blank plasma or blank brain 
homogenate sample spiked with known morphine concentrations. The 
recoveries and preconcentration factors (by LLE) were taken into account in 
calculation of the unknown morphine concentrations in animal samples. 
Microchip electrophoresis-electrospray ionization mass spectrometry
The microchips with electrospray emitter tip were fabricated of SU-8 
epoxypolymer as described in publication IV and in references [85] and [154] 
(Figure 7). The microchip comprised of a 25-mm long separation channel 
(50 μm × 50 μm, w×h, Leff 20 mm) intersected by a 10-mm-long injection 
channel (simple cross), and a 12-mm-long auxiliary channel (100 μm × 50 μm, 
w×h) providing sheath liquid to the integrated ESI emitter tip. Small 
polydimethylsiloxane (PDMS) sheets with 2 mm inlet holes were placed on top 
of the SU-8 chip to avoid sample spreading on the relatively hydrophilic SU-8 
before use. The microchip was filled and rinsed with water/methanol solution 
containing 40–60% (V/V) methanol and 20–40 mM ammonium acetate 
(BGE). 
Samples were loaded in pinched injection mode by applying an electric field 
between the sample inlet and the sample outlet, and a small focusing potential 
to the buffer inlet. The sheath liquid inlet was left floating during injection and 
thus no spray was produced. The electrophoretic separation was performed in 
cathodic mode by applying high voltage to the buffer inlet. The ESI voltage 
applied to the sheath liquid inlet also served as the counter voltage for MCE 
separation. Small push-back voltages were applied to the sample inlet and the 
sample outlet during the separation step to prevent sample leakage to 
separation channel. An external power supply (Micralyne, Edmonton, 
Canada) was used to apply the voltages through platinum wires that were 
placed on the microchip inlets. 
The Agilent 6330 ion trap mass spectrometer was equipped with an xyz-
alignment stage to replace the standard ion source. The SU-8 microchip was 
placed on the xyz-stage in front of the MS inlet. The mass spectrometer was 
operated in positive ion mode with a capillary voltage of -1.6 kV. An ESI 
voltage of 2.0–3.2 kV was applied to the sheath liquid inlet. The sheath liquid 
was methanol–water 80:20 (v/v) containing 1% (v/v) acetic acid. The excess 
separation current was led to ground via a 50 MΩ resistor that was coupled in 
parallel with the ES voltage supply. 
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4 RESULTS AND DISCUSSION
In the following chapters, the main results are presented and discussed in view 
of the aims of the thesis. Further details can be found in the original 
publications (I–IV) and the related supporting information files. 
4.1 DRUG METABOLISM AND PRECISION MEDICINE
4.1.1 EFFECT OF POROUS SILICON NANOPARTICLES ON 
CYTOCHROME P450 METABOLISM (I)
Nanoparticles are increasingly studied as new targeted, drug delivery methods 
in precision medicine. The safety of the nanoparticles is explored in terms of 
e.g., cytotoxicity, immune response, and biodegradation or accumulation in 
the body [155,156], but the effects on CYP enzymes are commonly neglected. 
Still, nanoparticles are known to accumulate in liver [157], where the CYP 
enzymes are also located. Few studies of gold and silver nanoparticles have 
shown potential interactions [158], but the porous silicon (PSi) nanoparticles 
have not been studied before. The properties of the studied nanoparticles are 
presented in Table 6. 
In this study the Michaelis-Menten kinetics were determined for four CYP 
enzymes with probe substrates recommended by the FDA: CYP1A2 
(phenacetin O-deethylation), CYP2A6 (coumarin 7-hydroxylation), CYP2D6 
(bufuralol 1’-hydroxylation), and CYP3A4 (testosterone 6β-hydroxylation). 
Out of these enzymes, CYP2D6 was most vulnerable to inhibition by all three 
types of nanoparticles. The enzyme activity (Vmax) was clearly decreased in the 
presence of each nanoparticle type even after corrections of the adsorption 
effects, whereas only minor changes in the Michaelis constant (Km) and 
intrinsic clearance (CLint) were observed (Figure 8). The CYP3A4 activity was 
slightly decreased in the presence of APTES-TCPSi and TCPSi, but only in the 
latter case a decrease in CLint was observed. Addition of Alkyne-THCPSi 
resulted in increase of both Vmax and Km of testosterone hydroxylation by 
CYP3A4, but the CLint was not affected. Both Vmax and Km of phenacetin O-
deethylation by CYP1A2 were decreased in the presence of all nanoparticle 
types. However, the CLint values for CYP1A2 in the presence of APTES-TCPSi 
and Alkyne-THCPSi were actually increased compared to the control. The Vmax 
of CYP2A6 was not affected by TCPSi, but the Km was decreased resulting in 
increased CLint. In turn, after addition of Alkyne-THCPSi the Vmax was 
decreased, whereas Km and CLint remained in the same level with the control. 
APTES-TCPSi caused slight increase in Vmax and CLint.  
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Table 6. Properties of the porous silicon nanoparticles (mean and standard deviation).
Alkyne-THCPSi APTES-TCPSi TCPSi
Surface charge - 30 mV + 35 mV - 30 mV
Hydrophilicity Hydrophobic Hydrophilic Hydrophilic
Particle size 184 nm 176 nm 159 nm
Pore diameter 12.1 ± 1.2 nm 8.0 ± 0.7 nm 10.7 nm
 
Figure 8 A-D) The maximum reaction rates (Vmax) relative to control (adjusted to 100%), E-H)
the Michaelis constants (Km), and I-L) the intrinsic clearances (CLint) of the CYP model 
reactions in the presence of the PSi nanoparticles. The error bars present the 
standard deviation (n = 4). The adsorption corrected values are marked by (a) after 
the name of the nanoparticle type. Results of Student’s t-test with Welch’s correction 
(above the bars): ***: p < 0.001; **: 0.001 < p < 0.01; *: 0.01 < p < 0.05; ns: not 
significant (p > 0.05). # The Km was so small that the Michaelis-Menten fit was not 
able to reliably predict it and thus the CLint could not be calculated. Adjusted with 
permission from ref. [159] originally published in European Journal of Pharmaceutical 
Sciences.
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The effects of the nanoparticles on CYP2D6 were further investigated with 
seven different nanoparticle concentrations (1 ng/mL–1 mg/mL) and a 
luminescence-based model reaction. The inhibition by APTES-TCPSi 
remained in the same level despite the nanoparticle concentration. More dose-
dependent inhibition was observed with the other two nanoparticle types, and 
the minimum inhibitory concentrations were 1 μg/mL for TCPSi and 
10 μg/mL for Alkyne-THCPSi. 
The three polymers investigated were block copolymers F68 and F127, and 
PVA, which are commonly used in nanoformulations together with the PSi 
nanoparticles. CYP2D6 was again most prone to inhibition (decreased Vmax) 
by all the studied polymers, but the intrinsic clearances were increased by the 
block copolymers as a result of simultaneous decrease of Km. The intrinsic 
clearance of CYP3A4 was not affected by any of the polymers, whereas Vmax 
and CLint of both CYP1A2 and CYP2A6 were increased by the block 
copolymers. PVA did not affect the intrinsic clearance of any enzyme. 
While statistically significant decreases in enzyme activities were observed, 
the inhibition mechanisms are not that obvious. Based on the changes in Vmax 
and Km the different reversible inhibition mechanisms can be distinguished, 
but irreversible inhibition causes similar changes as noncompetitive reversible 
inhibition and is thus difficult to detect based on enzyme kinetic parameters. 
The average size of the nanoparticles varied in the range of ca. 160–180 nm, 
whereas the active site cavities of CYP enzymes are typically below 3 nm3 in 
size.[160] Competitive binding to the active size is thus not likely. In addition, 
the cellular uptake of PSi nanoparticles by hepatocytes remains to be 
characterized in the future. However, the results indicate that the possibility 
of interactions should be studied also in vivo. CYP2D6 was shown to be the 
most vulnerable to inhibitory effects and as it is also highly polymorphic 
enzyme, the inhibitory effects may cause even stronger effects in populations 
with intrinsically lower CYP2D6 activity. Also, the combinatory effects of the 
nanoparticles and polymers are of interest, as they may either reinforce or 
compensate each others’ effects. 
4.1.2 MICROFLUIDIC PAPER-BASED DEVICE FOR STUDYING 
INDIVIDUAL DIFFERENCES IN CYTOCHROME P450 ACTIVITY (II)
The individual differences in CYP activities may be caused by polymorphic 
differences in the corresponding genes. These differences can be studied with 
genetic tests, which are relatively simple and fast, as described in the chapter 
1.1.3. However, also other than genetic factors can have significant effects on 
CYP activities, as described above in terms of the nanoformulations. These 
effects should also be considered as they can have equally strong impact on the 
safety and efficacy of the medication. The currently existing methods for 
studying the effects of the nongenetic factors are slow and laborious. The aim 
of this study was to develop a simple microfluidic platform for screening of 
individual differences in CYP enzyme activities. Instead of traditional 
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chromatographic paper, a paper-like coating based on FCC was used. The FCC 
coating was previously shown to be biocompatible material with low optical 
background and easily controlled wetting properties.[150] The 
characterization and optimization of the FCC coating and the assay design 
have been published by Jutila et al.[150] Also, activity of CYP enzymes on the 
μPAD device was preliminarily demonstrated. 
In this study, the assay was multiplexed and detection with conventional 
well-plate reader was investigated to enable simple and fast read-out. The 
assay was applied to analysis of individual differences in CYP enzyme 
activities. The CYP activities were studied with fluorogenic probe substrates 
(producing fluorescent metabolites) [161–163] instead of those recommended 
by the FDA. For a simple assay, easy readout is also required and the use of the 
fluorogenic substrates enabled fluorescence detection, which was not 
applicable for the reactions recommended by the FDA. 
Optimization of elution and detection
Fluorescent metabolites of six different CYP model reactions were 
preliminarily characterized for their suitability to enzyme activity screening on 
FCC platform. The assay consists of a reaction zone and a detection point 
separated by a semibarrier and separation channel. This enables separation of 
the metabolites produced in the reaction area from the CYP enzymes and 
NADPH, which may interfere with the fluorescence detection especially close 
to the UV range. The elution of the metabolites was examined by measuring 
the Rf values with different elution buffers and elution volumes (Table 7). In 
addition to efficient elution of the metabolite to the tip, the elution buffer 
affected to the detection of the metabolites and to the retention of the 
cosubstrate NADPH to the FCC. Borate buffer (20 mM, pH 10.0) was found 
optimal for elution and detection of all metabolites, except fluorescein, which 
was retained to the FCC coating through the whole separation channel. 
Phosphate buffer (pH 12) was the only buffer that enabled elution of 
fluorescein to the tip, but unfortunately it affected the FCC coating and the 
hydrophobic barriers, resulting in leakage from the hydrophilic areas to the 
hydrophobic areas. Thus, phosphate buffer could not be used, whereas in the 
other tested buffers (Tris buffer pH 7.5 or pH 9, MES buffer pH 6.5) 
fluorescein was not fluorescent, and it was excluded from further studies. After 
selection of the buffer, the elution volume was optimized for each metabolite. 
The minimum volume required for elution was previously determined to be 
25 μL [150], while the maximum volume hold by the hydrophobic AKD 
barriers was found to be 60 μL. 
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Table 7. Optimized parameters on μPAD for the fluorescent CYP metabolites.
Enzymea Substrate Metabolite Retention 
factorb
LOD Ex/em 
(nm)
CYP3A4 7-Benzyloxy-
resorufin
Resorufin 0.66 ± 0.13 0.02 pmol 579 / 597
CYP1A2 CEC CHC 0.77 ± 0.14 0.2 pmol 428 / 463
CYP2B6 7-MFC 7-HFC 0.59 ± 0.09 2 pmol 398 / 477
CYP2A6 Coumarin Umbelliferone 0.91 ± 0.09 2 pmol 367 / 447
CYP2D6 AMMC AMHC 2 pmol 382 / 447
a Only the CYP enzyme with highest activity in metabolism of the substrate is listed. 
b Rf value was measured 1 hour after elution by 25 μL of borate buffer. 
 
The detection was optimized by eluting the metabolites to the detection point 
in the tip of the channel (Figure 6) and by measuring the fluorescence signal 
with regular intervals until a stable signal was reached. The measurements 
were performed at RT and at 37 °C. The results showed clear increase in the 
fluorescence signal immediately after elution as the metabolites eluted to the 
tip. The maximal signal intensity was achieved between 20 and 80 min 
depending on the Rf value of the metabolite and the temperature (RT or 37 °C) 
which affected the capillary filling and evaporation rates. The signals of 
resorufin and 7-HFC remained stable after reaching the maximum for at least 
23 hours despite the evaporation of the liquid, whereas the signals of the other 
umbelliferone derivatives decreased rapidly after reaching the tip upon drying 
of the assay. Figure 9 shows the variation of the signal intensity after elution 
of umbelliferone and CHC. The time from elution to the maximal signal varied 
also depending on the metabolite concentration, and thus the assay readout 
was impractical in wetted state. Instead, the method was developed aiming at 
detection of the metabolites in dry state. After drying, the signal was stable at 
least up to 23 hours also in case of the umbelliferone derivatives. 
Figure 9 The effect of time on fluorescence signal of a) umbelliferone and b) 
cyanoumbelliferone (CHC) at room temperature (RT) and at 37 °C.
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The LOD of resorufin was shown to be only few tens of femtomoles, whereas 
the LODs of umbelliferone derivatives were in the range of few picomoles. The 
background signal derived from the assay platform itself increased as the 
excitation and emission wavelengths were decreased, which explains the 
higher background signal and thus decreased sensitivity of the umbelliferone 
derivatives. The estimated LODs are listed in the Table 7. Despite the better 
LODs before elution, the detection was not possible in these conditions in the 
enzymatic assays due to the background signal caused by other reaction 
components, and thus elution (separation) was necessary. 
Optimization of enzyme incubation conditions
The enzyme incubation conditions were optimized in terms of incubation 
temperature, NADPH amount, and incubation time. However, only the 
reactions mediated by CYP1A2 (CEC as substrate) and CYP2A6 (coumarin as 
substrate) produced sufficiently high amounts of the metabolites, CHC and 
umbelliferone, to enable accurate detection on the μPAD. Even resorufin, 
which had lower LOD than any of the other metabolites, was not formed in 
sufficiently high amounts. This was likely because of the turnover of 
7-benzyloxyresorufin to resorufin is reported to be low [161], although the 
molecular properties of the substrate may also complicate the assay. For 
example, the substrate, 7-benzyloxyresorufin, is poorly soluble in water and it 
was thus applied to the reaction area in solution containing 5% of DMSO, 
which is likely to decrease the enzyme activity.[164] On the other hand, if all 
DMSO was evaporated, the poor solubility of the substrate may also limit the 
redissolution of the substrate to the incubation buffer. 
The reactions of coumarin and CEC were studied at RT and at 37 °C. The 
CYP1A2 activity was not significantly altered by the incubation temperature, 
whereas the activity of CYP2A6 was higher at 37 °C as expected. However, 
further reactions were conducted at RT, because in these conditions smaller 
deviations were obtained (Figure 10a). The large variation at 37 °C is most 
likely result of uneven drying of the assays during the incubation. In these 
conditions, the evaporation is faster and the assays may dry out unless 
incubation buffer is added to the adsorbent pad during the incubation. 
The amount of cosubstrate NADPH should be high enough not to limit the 
reaction rate. Thus, the NADPH amount was optimized with CYP2A6 probe 
reaction (Figure 10b). As expected, the enzyme activity was increased when 
the amount of NADPH was increased from 1.5 nmol to 3.75 nmol, whereas 
further increase to 7.5 nmol did not increase the activity notably. The 
metabolite production could not be measured with NADPH amounts higher 
than 7.5 nmol, because the capability of the FCC coating to retain NADPH was 
exceeded and NADPH was eluted to the tip of the separation channel where it 
interfered with the detection of the metabolites. In further studies, 7.5 nmol of 
NADPH was used (corresponding to 5 mM concentration in the applied 
volume of 1.5 μL). 
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The incubation time was varied between 10 and 30 min at RT. 
Interestingly, a relatively small increase in metabolite production was 
observed for both CYP1A2 and CYP2A6 and the enzyme activities were actually 
decreased. (Figure 10c). Instead, a clear decrease in the background signal was 
observed as the incubation time increased (Figure 10d), especially at the 
wavelengths of umbelliferone detection. The origin of this background signal 
was related to incubation of NADPH, as the samples incubated without 
NADPH did not produce similar background signal, nor did nonincubated 
NADPH. The signal did not originate from NADPH itself because it did not 
elute to the tip. Thus, most probably NADPH reacts with the enzymes resulting 
in a fluorescent byproduct that is not retained by the FCC as strongly as 
NADPH itself. To maximize the metabolite production and the signal-to-noise 
ratio, incubation time of 30 min was selected for the final application. 
However, the almost equal metabolite production but smaller deviation would 
suggest that 20 min incubation time could improve the precision of the assay. 
Figure 10 a) Effect of incubation temperature on activity of CYP1A2 (amount of CHC produced)
and CYP2A6 (amount of umbelliferone produced). b) Effect of NADPH amount on 
production of umbelliferone by CYP2A6. c) Effect of incubation time on enzyme 
activity of CYP2A6 and CYP1A2. d) Effect of incubation time on background signal 
originating from NADPH by product on excitation and emission wavelengths used for 
detection of umbelliferone (367/477 nm) and CHC (428/463 nm). The error bars 
present the standard deviation (n = 3).
Individual differences in enzyme activities
The developed assay platform was applied to analysis of CYP1A2 and CYP2A6 
activities in HLM of three individuals. The activities were compared to average 
activities in a 20-donor pool of HLM. The assays were designed in a way that 
it enabled simultaneous determination of both enzyme activities for one donor 
as well as the activities of pooled HLM on a single FCC platform with 
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24 parallel assays. In Figure 11, the enzyme activities of each donor 
determined by the μPAD assay and by a conventional in-solution assay (in-
house), are presented relative to the pooled HLM (adjusted to 1, the dashed 
line). In addition, the values reported by the enzyme supplier are included for 
comparison. The supplier uses the same model reaction for determining 
CYP2A6 activity, but for CYP1A2 phenacetin O-deethylation is used. 
Figure 11 The CYP2A6 and CYP1A2 activities of the HLM from three different donors. The 
activities are presented as relative values compared to activity of pooled HLM 
(20 donors), which is adjusted to 1 (the dashed line). The activities were determined 
on the μPAD and in conventional in-solution assay (in-house) and compared to the 
activities reported by the supplier. The error bars show the standard deviation (n = 4).
The μPAD assay predicts markedly high CYP2A6 activity for donors 1 and 2, 
whereas donor 3 has slightly lower CYP2A6 activity compared to pooled HLM. 
The differences compared to pooled HLM determined by the in-solution assay 
are much smaller, but also opposite to those determined by the μPAD assay 
for donors 1 and 3. The observed CYP2A6 activities in the in-solution assay 
were similar to those reported by the supplier, which is expected as the same 
probe substrate and similar incubation conditions were used. The CYP1A2 
activities predicted by the μPAD assay were low compared to the pooled HLM 
for all donors. The supplier also reports activities of the donors to be close to 
the activity in pooled HLM or lower, whereas the in-solution assay shows 
slightly increased activities for donors 1 and 2. The CYP1A2 activity of donor 3 
is very low and similarly predicted by all the methods. 
Based on the results, further validation and improvement in precision and 
robustness are required to fulfill the requirements for a reliable diagnostic 
assay. In case of CYP1A2, the key difference between the in-solution assays 
performed in-house and by the supplier, was the probe substrate. The supplier 
uses a FDA-recommended probe, phenacetin, which is metabolized selectively 
by CYP1A2, whereas here the fluorogenic CEC was selected. CEC is also 
metabolized mainly by CYP1A2 in the liver, but some contributions from 
CYP2C9 and CYP2C19 are expected.[161,165] It has also been noted that use 
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of different probe substrates may end up in different results, especially in 
enzyme inhibition studies.[166] Also, the experimental conditions affect 
significantly and should be very carefully optimized. For CYP2A6, the same 
probe substrate was used in all cases, so that cannot explain the differences. 
On μPAD, the high background signal complicated the interpretation of 
CYP2A6 activities, though this effects should be similar for both the individual 
donor samples and the pooled sample, and thus not affect the relative 
activities. 
It can be concluded that at the current state, the FCC μPAD platform is not 
able to predict the enzyme activities with good enough reliability and 
robustness. However, the results clearly show that the CYP enzymes were 
active also on FCC at RT. Further optimization of the incubation protocol and 
conditions, as well as advances in the probe substrates are required before the 
developed platform can be used for real clinical analysis. Comparative studies 
of “conventional” probes recommended by the FDA and the fluorogenic probes 
have been conducted demonstrating the challenges of the fluorogenic 
probes.[162,167] Only few of these reactions are truly specific which 
complicates their use with HLM. In addition, the poor solubility of the 
substrates requires use of organic solvents which may result in enzyme 
inhibition even in amounts below 0.2% (V/V) in the reaction mixture.[164] 
Despite the challenges, the main reason for selecting fluorogenic probes over 
others, is typically the fast and simple readout of the fluorescence signal 
compared to e.g. LC-MS analysis. This was also aimed at in this study, as a 
more complex detection method would disable easy use e.g., in point-of-care 
applications and as a simple tool for precision medicine. 
4.2 MICROCHIP ELECTROPHORESIS IN 
PHARMACEUTICAL ANALYSIS
In this thesis, MCE methods were developed for three different 
pharmaceutical applications. First, MCE-EC was applied to analysis of CYP 
metabolism aiming at increased throughput compared to conventional 
analytical methods. The same device was also applied to targeted quantitative 
analysis of morphine from biological samples. This is a very typical analytical 
task in pharmaceutical research to obtain pharmacokinetic and 
pharmacological information by analyzing a drug or its metabolites e.g. in 
plasma. However, behavioral studies are commonly limited to observations of 
the animal, e.g. locomotor activity, eating etc. A simple, commercial analytical 
device with easy operation without special expertise, could provide additional 
chemical information and improve the outcome of the studies. The third 
application aims to demonstrate the power of MCE in an analytical task that is 
commonly challenging for conventional methods. Protein phosphorylation 
plays a significant role in e.g. cell proliferation, differentiation, and apoptosis. 
Abnormal phosphorylation has been connected to many diseases including 
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diabetes and cancers.[168] However, analysis of phosphopeptides in protein 
digests is challenging due to the low abundance and poor ionization efficiency 
(in MS) of the phosphopeptides. Thus, an MCE-ESI/MS method was 
developed for separation of nonphosphorylated peptide from the 
phosphorylated forms of the same peptide. In addition, further derivatization 
step was included to enable separation of positional phosphorylation isomers. 
4.2.1 ANALYSIS OF CYTOCHROME P450 METABOLISM
A commercial MCE-EC device was applied for analysis of FDA recommended 
CYP probe reactions.[152] Four metabolites, paracetamol (CYP1A2), 
umbelliferone (CYP2A6), 1’-hydroxybufuralol (CYP2D6), and 
6β-hydroxytestosterone (CYP3A4), were preliminarily studied. However, only 
paracetamol and umbelliferone showed high enough electroactivity to be 
detected with the MCE-EC method. 
The separation and detection conditions were optimized for both 
paracetamol and umbelliferone. The method showed good selectivity for both 
substrate-metabolite pairs: Coumarin was not electroactive with the selected 
WE potential and did not disturb the analysis of umbelliferone. Phenacetin 
(tmigr = 26.9 s) was detected in the selected conditions, but it was rapidly 
separated from paracetamol (tmigr = 37.2 s) by MCE. Phenacetin and 
paracetamol spiked in the enzyme incubation matrix (after termination of the 
reaction) could also be separated and detected with the same method without 
any additional clean-up steps. Both within-run and between-run precisions of 
the peak area were on acceptable level (Table 8). Detection and quantitation 
limits were in micromolar level determined from standard solutions. Based on 
the enzyme activities determined in publication I, the maximal amounts of 
paracetamol and umbelliferone formed in enzymatic reactions are 
approximately 10 μM and 5 μM, respectively. However, in study of enzyme 
kinetics or enzyme inhibition, detection of much lower concentrations is 
required. Thus, electrokinetic sample stacking was applied for analysis of 
paracetamol to enhance the detection sensitivity. The samples were prepared 
in more diluted buffer (compared to BGE) and injected to separation channel 
(electric field between sample inlet and buffer outlet). During the separation 
step, the decreased ionic concentration of the sample plug resulted in lower 
conductivity and higher electric field strength compared to BGE, and thus 
concentration of the negatively charged paracetamol to the end of the sample 
plug. By injecting the sample from sample inlet towards buffer outlet (instead 
of sample waste), the volume of sample plug was increased and determined by 
the loading time rather than channel geometry. Up to 3-fold increase of peak 
area was achieved with loading time of 15 s. Longer sample loading times 
resulted in large sample plugs in separation channel and significant peak 
broadening, and ended up in reduced sensitivity. Further optimization of 
sensitivity by e.g., additional sample concentration step before MCE, are 
required to enable CYP metabolism studies with the tested MCE-EC method 
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and the selected probes. Also model reactions with highly electroactive 
metabolites would improve the sensitivity and enable study of other CYP 
enzymes, including the most important drug-metabolizing enzymes CYP3A4 
and the highly polymorphic CYP2D6. 
Table 8. The validation results of MCE-EC method for analysis of paracetamol and 
umbelliferone.
Parameter Paracetamol Umbelliferone
Limit of detection 2.4 μM 3.9 μM
Limit of quantitation 7.4 μM 11.9 μM
Linear range 15–100 μM (R2 = 0.98263) 15–100 μM (R2 = 0.99067)
Within-run precisiona 6.1% (CV) 10.4% (CV)
Between-run precisionb 12.3% (CV) n.d.
a 6 injections, sample concentration 50 μM. 
b 3 injections on 3 different days, sample concentration 100 μM 
CV: coefficient of variation; n.d.: not determined 
4.2.2 ANALYSIS OF MORPHINE IN MOUSE PLASMA AND BRAIN (III)
The same commercial MCE-EC device described above was used to analyze 
morphine in mouse plasma and brain homogenate samples as a part of a 
behavioral animal study addressing morphine addiction. The separation 
voltage and WE potential were optimized and selected based on sensitivity and 
precision. Separation voltage of 1000 V (333 V/cm) enabled best separation 
efficiency and WE potential of 1 V provided highest sensitivity. Also, increase 
in sample volume applied to the sample inlet as well as increase in loading time 
increased the detected peak area. To further improve the peak shape, the ionic 
concentration of the sample buffer was decreased to 5 mM (20 mM in BGE) to 
enable further concentration of the sample during the separation step by 
electrokinetic sample stacking. The cationic morphine migrates faster in the 
sample plug concentrating in the front of the plug. 
An off-chip LLE was performed before the MCE-EC analysis. The LLE 
method enabled 2-fold enrichment of morphine in plasma samples and 16-fold 
enrichment in brain homogenate samples by adjusting the sample volume and 
the final volume after LLE. The recovery of morphine from plasma samples 
was only 24–31%, which was probably affected by the relatively high fraction 
of morphine bound in plasma proteins.[169] However, the 2-fold enrichment 
during LLE compensated the low recovery. The recovery of morphine from 
brain homogenate samples was much better (69% for 1 μM morphine) as 
expected due to lack of plasma proteins. 
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Figure 12 Electropherograms of morphine in different matrices compared with blank matrix. (a) 
5 μM morphine in 5 mM MES buffer, (b) 5 μM morphine in mouse plasma, and (c) 
1 μM morphine in mouse brain homogenate. Plasma and brain samples were treated 
with LLE before analysis and the residue was dissolved in 5 mM MES (pH 6.0) buffer 
after evaporating the extraction solvent. All separations were performed at 333 V/cm 
using 20 mM MES (pH 6.5) as the BGE and working electrode potential of 1.0 V. The. 
Reprinted from ref. [170] originally published in Scientific Reports licensed under CC-
BY 4.0 https://creativecommons.org/licenses/by/4.0/. 
The method was validated in terms of selectivity (Figure 12), linearity, limit of 
quantitation, within-run and between-run precision, and accuracy according 
to the FDA guidelines.[153] The validation results and the FDA requirements 
are presented in Table 9. The lower limit of quantitation (LLOQ) was 0.4 μM 
which corresponds to only 20 amol of morphine in the injected volume (50 pL 
based on the injection cross geometry). Within-run precision between 3.7 and 
12.3% (CV, 6 injections on each concentration) was achieved for morphine in 
plasma samples, but the between-run precision (4 injections on 3 different 
days) were higher, especially at 1 μM concentration, where the method was not 
able to meet the FDA criteria. To overcome the deviation between days, the 
calibration curve was established separately on each day. The accuracy was 
also good at 5 and 20 μM concentrations, but again at 1 μM concentration the 
accuracy was slightly outside the FDA limits. However, the concentrations 
measured in this study, were above 5 μM and thus the method was considered 
suitable for quantitation of morphine in plasma. For morphine (1 μM) in brain 
homogenate within-run precision of 7.7% (CV) and accuracy of 89.6% was 
achieved. 
The sensitivity was in a relatively good level and similar to that achieved in 
a previous study for morphine in urine samples.[103] The method applied in 
urine analysis was, however, not suitable for analysis of small volume samples, 
as an off-chip conventional solid-phase extraction was performed prior to 
MCE-EC analysis. Thus, in this thesis, LLE was selected as a sample 
preparation method because it is easily scalable based on the available sample 
volume. The volume of the plasma samples was only few tens of microliters, 
whereas the brains were homogenized in 5 milliliters of water. On the other 
hand, the morphine concentration in plasma was much higher than in the 
brain homogenate. The LLE method was suitable for both matrices as it 
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enabled higher enrichment factor for brain homogenate samples to reach 
concentrations above LLOQ in LLE-treated samples and treatment of plasma 
samples with less enrichment, but small volume. 
Table 9. Method validation results for analysis of morphine by MCE-EC.
Parameter Value FDA criteria OK?
Lower limit of quantitationa (n = 4) 0.4 μM (16.1% CV) CV < 20% OK
Linear rangea 0.5–20 μM
Coefficient of variation (n = 5) 1.1–10.9% < 15% OK
Deviation from nominal concentration 0.3–7.7% < 15% OK
Between-run precision of peak area (CV)a (n = 4 on 3 different days)
1 μM 29.4% < 15% NO
5 μM 5.3% < 15% OK
20 μM 7.9% < 15% OK
Within-run precision of peak area (CV)b (n = 6)
1 μM 12.3% < 15% OK
5 μM 3.7% < 15% OK
20 μM 4.5% < 15% OK
Accuracyb (n = 6)
1 μM 119.2% 85–115%c NO
5 μM 106.9% 85–115% OK
20 μM 100.7% 85–115% OK
a Determined from standard samples. 
b Determined from spiked plasma samples. 
c The FDA guideline requires that the mean value is within 15% of the actual value corresponding to 
accuracies 85–115%. 
Figure 13 The detected morphine concentrations in plasma (scatter graph, left y-axis) and brain 
(bar graph, right y-axis) for each mouse. The mice no. 1–10 were administered 
morphine hydrochloride (20 mg/kg), whereas the mice no. 11–20 were not treated 
with morphine. The error bars represent propagated error based on precision and 
recovery. Revised from ref. [170] originally published in Scientific Reports licensed 
under CC-BY 4.0 https://creativecommons.org/licenses/by/4.0/.
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One of the aims of this study was also to evaluate the feasibility of the 
commercial portable MCE-EC system for routine use in e.g., animal research 
facilities. The chemical information that could be easily achieved on-site, 
would offer additional data for behavioral animal studies. A targeted 
application could easily be optimized, as demonstrated in this study, to enable 
simple quantitative analysis. Also considering the use of the method outside 
analytical chemistry laboratory, LLE is more suitable sample preparation 
method as it does not require any additional instrumentation. Even 
integration of the LLE on the microchip could be feasible with e.g., similar 
method previously demonstrated for drug metabolism studies.[96] 
The developed method was applied to analysis of mouse plasma and brain 
samples derived from a behavioral study. Plasma samples of 10 mice treated 
with morphine and another 10 mice without morphine treatment were 
analyzed. The morphine plasma concentrations were between 6.7 and 17 μM 
(Figure 13). No morphine was detected in the plasma of non-treated mice. The 
detected plasma concentrations were in line with previous studies.[171] In 
addition, brain homogenate samples of five mice treated with morphine were 
analyzed. The concentrations of morphine in brain followed the same trend as 
in plasma in four cases out of five. 
4.2.3 SEPARATION OF PHOSPHOPEPTIDES (IV)
In publication IV, the MCE technology combined with ESI/MS detection was 
challenged in an analytical task commonly difficult for many conventional 
techniques. Analysis of phosphopeptides is difficult due to their low 
abundance in protein digestions and their poor ionization efficiency 
(compared to corresponding nonphosphorylated peptide) in electrospray. In 
addition, the positional phosphorylation isomers (same peptide with same 
number of phosphorylations but on different amino acid residues) are not 
possible to separate based on their mass/charge (m/z) ratio and even the 
interpretation of MS/MS spectra is commonly challenging. Insulin receptor 
peptide (IR0, amino acids 1142–1153 of the insulin receptor) was selected as a 
model compound with the corresponding peptides with one phosphorylation 
at tyrosine 1146 (IR1A) or at tyrosine 1150 (IR1B), and all three tyrosine 
residues (1146, 1150, and 1151) phosphorylated (IR3). 
The separation conditions were optimized, including the separation 
voltage, ionic strength of BGE, and methanol content of the BGE. The selected 
BGE consisted of 40% of water and 60% of methanol (V/V) including 30 mM 
ammonium acetate (pH 7.4). The monophosphorylated peptides and the triply 
phosphorylated peptide were separated from the nonphosphorylated peptide 
at electric field strength of 750 V/cm in less than 40 s (Figure 14). The within-
run precision of the migration times was 7.5–11.3% (CV, n = 5) without 
internal standard and 3.1–4.7% (CV, n = 5) with the nonphosphorylated 
peptide as internal standard. The nonphosphorylated peptide migrated at 
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20.0 ± 1.7 s, monophosphorylated peptides at 22.8 ± 1.7 s (single peak), and 
triply phosphorylated peptide at 27.5 ± 3.1 s (n = 5). 
To enable separation of the monophosphorylated peptide isomers, a 
derivatization protocol was applied. The derivatization reagent, 
9-fluorenylmethyl (Fmoc) binds to amino groups of the peptides. Insulin 
receptor peptide has four amino groups: two close to the N-terminal end 
(threonine and arginine), and two close to the C-terminal end (lysine and 
arginine). Both rapidly reacting Fmoc-Cl and much slower Fmoc-OSu were 
examined. The derivatization products were first analyzed by direct infusion 
MS and MS/MS. In the MS spectra of the IR1A isomer, a doubly derivatized 
peptide (Fmoc2-IR1A) was observed after reaction with Fmoc-Cl (Figure 15). 
The same reaction of IR1B produced mainly a singly derivatized (Fmoc-IR1B) 
product. The MS/MS spectra of both derivatization products showed that the 
Fmoc-product was formed by reaction of an amino group close to the 
N-terminal end, whereas in the Fmoc2-product another amino group close to 
the C-terminal end was also derivatized. The phosphorylation near the 
C-terminal end of IR1B most likely prevented reaction of the amino groups 
close to the C-terminal end and thus resulted in singly derivatized product in 
the rapid 10 min reaction. Based on these results, derivatization may enable 
separation of the isomers based on m/z ratio if the phosphorylation is close to 
the derivatized group and thus prevents the reaction. In turn, the slow 
derivatization by Fmoc-OSu resulted in Fmoc2-products of both isomers. 
The formation of different derivatization products may not be achieved in 
all cases, especially with more complicated samples, and it may also require a 
lot of optimization. Thus, the derivatization products were analyzed by MCE-
ESI/MS. In addition to the Fmoc2-IR1A product, a small peak of singly 
derivatized Fmoc-IR1A was observed after separation by MCE. However, even 
the reaction products Fmoc-IR1A and Fmoc-IR1B with the same m/z values 
could be separated by the MCE method (E = 150 V/cm) prior to MS analysis 
with migration times of 27.1 s (Fmoc-IR1A) and 34.6 s (Fmoc-IR1B). Similarly, 
the Fmoc2-products formed in the reaction with Fmoc-OSu could be separated 
by the MCE method (E = 500 V/cm) with migration times of 27.4 s (Fmoc2-
IR1A) and 32.7 s (Fmoc2-IR1B). The MCE separation also revealed Fmoc-IR1B 
product (tmigr = 27.0 s) formed in the reaction with Fmoc-OSu, that was 
detected only after separation from the Fmoc2-IR1B product (tmigr = 32.7 s). 
The repeatability of migration times was good for all the reaction products 
(4.0–6.1% CV, n = 3, no IS). Overall, the developed method showed good 
performance in analysis of simple peptide samples. For further evaluation of 
the performance, the method should be applied to analysis of digested protein 
samples. 
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Figure 14 The extracted ion electropherograms of the most abundant [M + 2H]2+ ions of the 
nonphosphorylated peptide (IR0), the monophosphorylated peptides (IR1A and 
IR1B), and the triply phosphorylated peptide (IR3), 50 μM each, separated by the 
optimized MCE-ESI/MS method. Reprinted with permission from ref. [172] originally 
published in Journal of Chromatography A.
 
Figure 15 The MS spectra of derivatization products a) Fmoc2-IR1A and b) Fmoc-IR1B from 
reaction with Fmoc-Cl. Adjusted with permission from ref. [172] originally published 
in Journal of Chromatography A.
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5 SUMMARY AND CONCLUSIONS
In this thesis, the possibilities of microfluidic analytical devices in 
pharmaceutical research were demonstrated in selected applications with 
different analytical requirements. Special emphasis was put on requirements 
of drug metabolism studies and precision medicine. 
One approach to more effective medication is targeted drug delivery with 
help of nanocarriers. In publication I, the risk of interactions between the PSi 
nanoformulations and CYP enzymes was demonstrated by study of enzyme 
kinetic parameters in pooled HLM. The highly polymorphic CYP2D6 was most 
affected by the studied nanoparticles with up to 60% loss of activity in the 
presence of TCPSi particles. The actual mechanisms, as well as the cellular 
uptake of the nanoparticles by hepatocytes have not been determined and 
should be investigated to understand the overall effects in vivo. The “assay 
cascade” for full characterization of nanomaterials developed by the European 
Nanomedicine Characterisation Laboratory (EUNCL) includes physical and 
chemical properties, as well as screening of immunological, hematological, 
and toxicological properties in vitro.[173] However, the effects on CYP 
metabolism are not included despite the critical role of these enzymes in 
metabolism of both drugs and other xenobiotics. 
In addition to xenobiotics, also individual characteristics, including genetic 
polymorphism, age, sex, and disease, as well as other environmental factors, 
cause significant inter-individual variation in CYP activity. Taking these 
differences into account in selection of the most efficient and safe treatment 
for each patient individually, is important aspect of precision medicine. 
Genetic tests for most common polymorphic variants of CYP2D6, CYP2C9, 
and CYP2C19 have been developed and commercialized.[10,42] However, 
these test do not recognize rare variants, and even more importantly, all the 
other factors affecting the CYP activities are not considered. 
In publication II, a simple microfluidic platform (based on paper-like FCC 
coating) for screening of the individual differences in enzyme activities was 
developed and preliminarily characterized. A lot of further optimization and 
characterization is still required to improve sensitivity, accuracy, and precision 
of the personalized CYP screening. The basic idea of the platform was however 
demonstrated by analyzing CYP1A2 and CYP2A6 activities in liver microsomes 
from three individual donors. The amount of microsomes required for the 
analysis is very small and thus microsomes can be prepared of liver biopsy. 
Although liver biopsy is a medical procedure, that requires also trained 
personnel, and more invasive than a simple finger prick to obtain a drop of 
blood, the proposed approach does not require administration of a cocktail of 
probe drugs with high risk of adverse effects. The assay was also designed to 
be compatible with conventional well-plate reader and thus does not require 
any special instrumentation. The study of enzyme activities from liver 
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microsomes would most likely be best suited for situations where liver biopsy 
is relevant also for diagnosis etc. For example, the patients with hepatocellular 
carcinoma, the most common type of cancer in liver, suffer also from severe 
liver dysfunction, including changes in CYP metabolism.[174] Together with 
multiple medications for the cancer, the risk of adverse effects and toxicity 
related CYP metabolism can be highly increased. 
Advanced miniaturized analytical separation systems, including microchip 
electrophoresis, enable analysis of more complex samples. MCE is a widely 
studied separation method, which benefits from miniaturization. The 
feasibility of a commercial MCE-EC device for CYP metabolism studies [152] 
and analysis of morphine from plasma and brain samples (III) was evaluated. 
The method developed for CYP metabolism studies showed good precision and 
LODs in low micromolar range. However, the sensitivity of the system was not 
sufficient for CYP metabolism studies with the probe reactions recommended 
by the FDA. Instead, the sensitivity of the system was found to be sufficient for 
analysis of morphine in biological matrices. A quantitative method, including 
off-chip LLE and on-chip electrokinetic stacking, was developed with good 
precision and accuracy. This kind of simple, small, and relatively cheap 
commercial device could be beneficial also in other laboratories than those 
focusing on analytical chemistry. It is especially suitable for targeted analysis 
of electroactive compounds and further improvements in automatization and 
integration of the sample handling would enhance the applicability of the 
system by also operators without special expertise in analytical chemistry. A 
targeted method could be used e.g., to provide chemical information in 
addition to behavioral monitoring in animal research facilities. 
The capability of MCE was also demonstrated in a more challenging 
analytical task i.e., separation of phosphopeptides and especially the 
positional phosphorylation isomers (IV). MCE was combined to mass 
spectrometric detection via monolithically integrated ESI tip on the 
microchip. The developed method was able to separate nonphosphorylated 
insulin receptor peptide from the corresponding monophosphorylated and 
triply phosphorylated peptides with same amino acid sequence in less than 
40 s. The monophosphorylated isomers with identical m/z ratio could not be 
separated in their native form and thus a derivatization protocol was applied. 
The rapid derivatization by Fmoc-Cl resulted in different reaction products, 
with different m/z values, of the two isomers enabling their separation by MS. 
Instead, the slow overnight derivatization by Fmoc-OSu, resulted mainly in 
the Fmoc2-product of both monophosphorylated isomers. However, even the 
similar Fmoc2-products with equal m/z values could be separated by MCE 
before the MS analysis. To demonstrate the suitability of the method, further 
studies with digested protein samples should be performed. The more complex 
samples, with a wide variety of different peptides, will challenge the method, 
especially considering the low abundance of the phosphopeptides. An 
additional (on-chip) phosphopeptide enrichment step might be necessary 
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before derivatization and separation of the positional phosphopeptide 
isomers. 
In all, the work described in this thesis provides a glimpse into the 
possibilities of microfluidic analytical techniques in pharmaceutical research. 
The simplicity, speed, low costs, and parallelization makes these techniques 
highly interesting in a variety of applications. The envisioned use of the 
simplest equipment-free devices (including μPADs) for point-of-care 
diagnostics in the developing countries, can be one of the future applications 
of microfluidics. Still, need for fast and simple analytical techniques does exist 
also in the developed countries. For example, the increasing interest in 
precision medicine will require tools that enable identification of the 
individual characteristics that are considered to select the most safe and 
effective treatment for each patient. Miniaturized analytical techniques could 
be powerful also in these applications in the future. Microchip electrophoresis, 
the most commonly miniaturized separation technique, is not yet in a position 
where it would be widely applied in routine analysis. Especially, the robustness 
is often questioned. The MCE-EC method developed in this thesis 
demonstrated repeatable quantitative analysis, and more validated 
quantitative methods are needed to convince the possible users outside the 
“microfluidic community”. Further advances in integration of additional steps 
on the same microchip and increase in the level of automatization will also 
enhance the way of MCE to routine use in pharmaceutical research. 
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